

Subject Index—Volume 79

No. 1, January 1, pp. 1-202
 No. 2, January 15, pp. 203-424
 No. 3, February 1, pp. 425-634
 No. 3, February 1, Supplement, pp. 635-664
 No. 4, February 15, pp. 665-868
 No. 5, March 1, pp. 869-1060

No. 6, March 15, pp. 1061-1270
 No. 7, April 1, pp. 1271-1452
 No. 8, April 15, pp. 1453-1640
 No. 9, May 1, pp. 1641-1852
 No. 10, May 15, pp. 1853-2062
 No. 11, June 1, pp. 2063-2274
 No. 12, June 15, pp. 2275-2482

A

ACTH, after bone marrow/blood-derived progenitor cell transplant, 1617
 Actinic keratoses, metastatic squamous cell carcinoma from, 920
 Actinomycin-D, for rhabdomyosarcoma, hepatic venoocclusive disease and, 2435
 Acute leukemia. *See* Leukemia
 Adenocarcinoma. *See specific sites*
 Adenomatous hyperplasia, atypical, associated lung cancer and, prognosis of, 1521
 Adolescents. *See also* Children
 insular thyroid cancer in, 1044
 neuroblastoma in, 2028
 testicular germ cell tumors in, CD34 in, 2430
 Adrenocortical function, after bone marrow/blood-derived progenitor cell transplant, 1617
 Adriamycin. *See* Doxorubicin
 Adult T-cell leukemia/lymphoma, vs. cutaneous T-cell lymphoma, HTLV-1 and, 269
 Aerobic exercise, in postchemotherapy rehabilitation, 1717
 African Americans
 breast-conserving surgery for, 314
 colorectal adenocarcinoma in, 441
 lung cancer in, smoking and, 45
 prostate cancer in, 99
 Age
 in acute lymphoblastic leukemia, socioeconomic status and, 2045
 astrocytoma prognosis and, 370
 in clear cell carcinoma of vagina and cervix, 2229
 prostate cancer and, 99
 AICA (automated image capture and analysis), in uveal melanoma, 982
 Alanine aminotransferase, recurrent hepatocellular carcinoma and, 688
 Alcohol, gastric cancer and, 1840 (letter)
 Alkaline sphingomyelinase, in colorectal cancer, 448
Allium sativum, for bladder cancer, 1987
 All-trans retinoic acid, for cervical cancer, 1574
 American Cancer Society

California Division, Managed Health Care Conference, Feb. 1 supplement
 Mission 2000 and, 658
 5-Aminolevulinic acid-based photodynamic therapy, 2282
 Anal cancer, radiation therapy for, with/without chemotherapy, 2329
 Analgesia, oxycodone for, vs. hydromorphone, 1429
 Anaplastic astrocytoma, proliferation index in, prognosis and, 849
 Anastrozole, for breast cancer, 730
 Anemia, chemotherapy-related, erythropoietin for, 1623
 Angiogenesis
 in esophageal cancer, vascular endothelial growth factor and, 206
 in prostate cancer, prognosis and, 772
 Anorectal melanoma, 18
 Antibiotic lozenge, for radiation mucositis, 2193
 Anticytokine therapy, for cachexia, 1828
 Antiemetics, dolasetron as, 1216
 Anti-Fas monoclonal antibodies, in bladder cancer, doxorubicin and, 1180
 Antigen(s). *See also specific antigens*
 carcinoembryonic
 in anorectal melanoma, 18
 in lung cancer, postoperative time-course of, prognosis and, 1533
 epithelial membrane, in anorectal melanoma, 18
 Ki-67, in prostate cancer, postoperative recurrence and, 952
 prostate specific
 doubling time of, idarubicin and, 1703
 free to total ratio of, 90
 prostate volume and, 104
 prognosis and, 1370, 2154
 radiotherapy results and, 328, 337
 sialyl Lewis
 in lung cancer, 1678
 in melanoma, 1686
 Anti-HTLV-1 antibody positive cutaneous T-cell lymphoma, 269
 Antithymocyte globulin, for hypoplastic myelodysplastic syndrome, 1548

Subject Index—Volume 79

No. 1, January 1, pp. 1-202
 No. 2, January 15, pp. 203-424
 No. 3, February 1, pp. 425-634
 No. 3, February 1, Supplement, pp. 635-664
 No. 4, February 15, pp. 665-868
 No. 5, March 1, pp. 869-1060

No. 6, March 15, pp. 1061-1270
 No. 7, April 1, pp. 1271-1452
 No. 8, April 15, pp. 1453-1640
 No. 9, May 1, pp. 1641-1852
 No. 10, May 15, pp. 1853-2062
 No. 11, June 1, pp. 2063-2274
 No. 12, June 15, pp. 2275-2482

A

ACTH, after bone marrow/blood-derived progenitor cell transplant, 1617
 Actinic keratoses, metastatic squamous cell carcinoma from, 920
 Actinomycin-D, for rhabdomyosarcoma, hepatic venoocclusive disease and, 2435
 Acute leukemia. *See* Leukemia
 Adenocarcinoma. *See specific sites*
 Adenomatous hyperplasia, atypical, associated lung cancer and, prognosis of, 1521
 Adolescents. *See also* Children
 insular thyroid cancer in, 1044
 neuroblastoma in, 2028
 testicular germ cell tumors in, CD34 in, 2430
 Adrenocortical function, after bone marrow/blood-derived progenitor cell transplant, 1617
 Adriamycin. *See* Doxorubicin
 Adult T-cell leukemia/lymphoma, vs. cutaneous T-cell lymphoma, HTLV-1 and, 269
 Aerobic exercise, in postchemotherapy rehabilitation, 1717
 African Americans
 breast-conserving surgery for, 314
 colorectal adenocarcinoma in, 441
 lung cancer in, smoking and, 45
 prostate cancer in, 99
 Age
 in acute lymphoblastic leukemia, socioeconomic status and, 2045
 astrocytoma prognosis and, 370
 in clear cell carcinoma of vagina and cervix, 2229
 prostate cancer and, 99
 AICA (automated image capture and analysis), in uveal melanoma, 982
 Alanine aminotransferase, recurrent hepatocellular carcinoma and, 688
 Alcohol, gastric cancer and, 1840 (letter)
 Alkaline sphingomyelinase, in colorectal cancer, 448
Allium sativum, for bladder cancer, 1987
 All-trans retinoic acid, for cervical cancer, 1574
 American Cancer Society

California Division, Managed Health Care Conference, Feb. 1 supplement
 Mission 2000 and, 658
 5-Aminolevulinic acid-based photodynamic therapy, 2282
 Anal cancer, radiation therapy for, with/without chemotherapy, 2329
 Analgesia, oxycodone for, vs. hydromorphone, 1429
 Anaplastic astrocytoma, proliferation index in, prognosis and, 849
 Anastrozole, for breast cancer, 730
 Anemia, chemotherapy-related, erythropoietin for, 1623
 Angiogenesis
 in esophageal cancer, vascular endothelial growth factor and, 206
 in prostate cancer, prognosis and, 772
 Anorectal melanoma, 18
 Antibiotic lozenge, for radiation mucositis, 2193
 Anticytokine therapy, for cachexia, 1828
 Antiemetics, dolasetron as, 1216
 Anti-Fas monoclonal antibodies, in bladder cancer, doxorubicin and, 1180
 Antigen(s). *See also specific antigens*
 carcinoembryonic
 in anorectal melanoma, 18
 in lung cancer, postoperative time-course of, prognosis and, 1533
 epithelial membrane, in anorectal melanoma, 18
 Ki-67, in prostate cancer, postoperative recurrence and, 952
 prostate specific
 doubling time of, idarubicin and, 1703
 free to total ratio of, 90
 prostate volume and, 104
 prognosis and, 1370, 2154
 radiotherapy results and, 328, 337
 sialyl Lewis
 in lung cancer, 1678
 in melanoma, 1686
 Anti-HTLV-1 antibody positive cutaneous T-cell lymphoma, 269
 Antithymocyte globulin, for hypoplastic myelodysplastic syndrome, 1548

- Apoptosis
 in colorectal cancer, K-*ras* oncogene and, 1106
 in gastric cancer, 433
 5-fluorouracil and, 12
 in ovarian cancer, progesterone and, 1944
 Apoptosis receptors, on gastric cancer, 433
 Appendix, carcinoid tumors of, 804
 Ara-C. *See* Cytosine arabinoside
 Argyrophilic nucleolar organizer regions
 in oral squamous cell carcinoma, 2200
 in prostate cancer, 1956
 Artificial neural networks, in staging, 857
 Aspiration biopsy, in pancreatic cancer, 1780
 Astrocytoma
 in adults, 127
 classification and grading of, 1381
 descriptive epidemiology of, in France, 1195
 proliferation index in, prognosis and, 849
 supratentorial WHO grade 2, prognostic factors for, 370
 Atomic bomb survivors, salivary gland tumors in, 1465
 Atrial myxoma, 1809
 Atrial natriuretic peptide, ectopic, in small cell lung cancer, 35
 Atypical adenomatous hyperplasia, lung cancer associated with, prognosis of, 1521
 Atypical fibroxanthoma, LN-2 in, vs. in malignant fibrous histiocytoma, 2115
 Auerbach, Oscar, 1853 (obituary)
 Autologous peripheral stem cell transplant
 for breast cancer, with chemotherapy, nausea and vomiting after, 1699
 endocrine function and bone metabolism after, 1617
 rehabilitation after, aerobic exercise in, 1717
 Autologous tumor killing activity, in nonsmall cell lung cancer, prognosis and, 474
 Automated image capture and analysis, in uveal melanoma, 982
 Axillary nodal metastasis, in T1 breast cancer, predictors of, 1918
- B**
- Baby powder, ovarian cancer and, 2396
 Basaloid squamous cell carcinoma, of esophagus, 1865
 B-cell lymphoma, extranodal marginal zone, gastric pseudolymphoma as, 1656
bcl-1/cyclin D1 gene, in squamous cell laryngeal cancer, 1114
bcl-2
 in esophageal cancer, lymph node metastasis and, 1287
 in prostate cancer, postoperative recurrence and, 952
 Behcet's syndrome, with myelodysplastic syndromes, 262
 Benign prostatic hyperplasia, free to total prostate specific antigen in, prostate volume and, 104
 Beta-carotene, thyroid cancer and, 2186
 Bile duct cancer, laparoscopic staging of, 1315
 Binet's modified regimen, for chronic lymphocytic leukemia, vs. chlorambucil, 2187
- Biopsy
 fine needle aspiration, in pancreatic cancer, 1780
 open breast, preoperative prediction for, 1822
 in prostate cancer, after radiation therapy, 81
 Black, Maurice M., 203 (obituary)
 Blacks. *See* African Americans
 Bladder cancer
 advanced, chemotherapy for, 110
 after radiotherapy for prostate cancer, 1600
 diagnosis of, telomerase in, 362
 doxorubicin for, Fas-mediated cytotoxicity and, 1180
 garlic for, 1987
 platelet-derived endothelial cell growth factor in, 1190
 small cell neuroendocrine, 356
 transitional cell, cyclin D1 overexpression in, 780
 Blood-derived progenitor cell transplant, endocrine function and bone metabolism after, 1617
 Bombesin, in gut protection, in chemotherapy, 1794
 Bone
 choroid sarcoma of, 1903
 fractures of, luteinizing hormone-releasing hormone agonists and, in prostate cancer, 545
 malignant fibrous histiocytoma of, clinicopathology of, 482
 myxoid chondrosarcoma of, 1903
 osteogenic sarcoma of. *See* Osteosarcoma
 tumors of. *See also specific types*
 peritumoral edema in, prostaglandin and, 255
 Bone marrow transplantation
 endocrine function and bone metabolism after, 1617
 for epipodophyllotoxin-induced acute myeloid leukemia, 1049
 for testicular germ cell tumors, with chemotherapy, 1605
 Bone metabolism, after bone marrow/blood-derived progenitor cell transplant, 1617
 Bowen's disease, of hands, human papillomavirus in, 1911
 Brain metastases
 in colorectal cancer, long-term survivors of, 1842 (letter)
 in melanoma, in children, 2440
 from pediatric solid tumors, 403
 stereotactic radiosurgery for, 551
 Brain tumors. *See also specific types*
 astrocytoma
 in adults, 127
 classification and grading of, 1381
 descriptive epidemiology of, in France, 1195
 proliferation index in, prognosis and, 849
 supratentorial WHO grade 2, prognostic factors for, 370
 central neurocytoma, prognosis in, 790
 CNS lymphoma, increasing incidence of, 2409
 gangliogliomas, in adults, 127
 germinoma, spontaneous regression of, 558

- gliomas
 classification and grading of, 1381
 descriptive epidemiology of, in France, 1195
 18-fluorodeoxyglucose uptake by, survival and, 115
 proliferation index in, prognosis and, 849
 medulloblastoma, recurrent, treatment of, 1241
 pathologic diagnosis of, consultation for, 796
- BRCA1 testing, for breast cancer
 reaction to, 2219
 utility of, 2063, 2066 (editorials)
- Breast biopsy, open, preoperative prediction for, 1822
- Breast cancer
 anastrozole for, 730
 BRCA1 testing in, 2063, 2066 (editorials), 2219
 breast-conserving therapy for
 early stage I-II synchronous bilateral, 1362
 race and socioeconomic status and, 314
 recurrence after, calcifications and, 1355
 surgical margins in, 1453, 1459 (editorials), 1568
 chemotherapy for, 740
 neutropenia and fever and, 1150
 pregnancy after, 1271
 retained sensitivity to, 2137
 with stem cell transplant, nausea and vomiting after, 1699
 dienogest for, 169
 eukaryotic initiation factor 4E in, 2385
 genetic susceptibility testing for
 reactions to, 2219
 utility of, 2063, 2066 (editorials)
 increasing incidence and declining mortality in, 69
 invasive, in situ carcinoma-associated immunity in, 1846 (letter)
 metastatic, cathepsin D in, 2132
 mitoxantrone, 5-FU and leucovorin vs. cyclophosphamide, 5-FU and methotrexate for, 740
 mortality in
 declining, 69
 screening and, 1 (editorial)
 multidisciplinary clinics for, 2380
 in National Cancer Data Base, vs. in SEER program, 2052
 nm23 in, metastatic potential and, 1158
 nodal metastasis in, prediction of, 1856, 1862 (editorials)
 pelvic computed tomography in, 500
 pregnancy after, 1271
 radiation therapy for
 in locally advanced disease, 1138
 postmastectomy, 669
 after radiotherapy for Hodgkin's disease, 1203
 scatter factor and *c-met* receptor in, 749
 screening for
 mortality rates and, 1 (editorial), 69
 risk-benefit analysis for, 628 (letter)
 in younger women, survival and, 1923
 small node-negative invasive, clinicopathology and prognosis in, 761
 staging in, artificial neural networks for, 857
 Stein-Leventhal syndrome and, 494
 stress and, 1055 (letter)
 surgery for
 breast-conserving. *See* Breast cancer, breast-conserving therapy for
 race and socioeconomic status and, 314
 radiation therapy after, 669, 1061, 1067 (editorial)
 reconstructive, silicone implants in, 1747
 T1, axillary nodal metastasis in, predictors of, 1918
 thermography in, 187 (letter)
 thyroid metastases in, 574
 in younger women, method of detection and, survival and, 1923
- Breast cancer clinics, multidisciplinary, 2380
- Breast-conserving surgery
 for early stage I-II synchronous bilateral cancer, 1362
 margins in, 1453, 1459 (editorials), 1568
 race and socioeconomic status and, 314
 recurrence after, calcifications and, 1355
 surgical margins in, 1453, 1459 (editorials), 1568
- Breast implants, silicone, health implications of, 1747
- Breast tissue, scatter factor and *c-met* receptor in, 749
- Bronchogenic carcinoma. *See also* Lung cancer
 postoperative carcinoembryonic antigen time-course in, prognosis and, 1533
- ## C
- Cachexia, proinflammatory cytokines and, 1828
- Calcifications, after breast-conserving therapy, recurrence and, 1355
- Calcium homeostasis, after bone marrow/blood-derived progenitor cell transplant, 1617
- Call-Exner bodies, in granulosa cell tumor of ovary, prognosis and, 1951
- Cancer. *See also specific sites and types*
 familial, chromosome 9 aberrations and, 1527
 in HIV infection, 1004
 HPV-associated, interferon for, 924
 second, in neurofibromatosis type 1, 1438
 terminal
 cognitive impairment in, 835
 psychiatric morbidity in, 1848 (letter)
- Cancer cachexia, proinflammatory cytokines and, 1828
- Cancer pain, oxycodone for, vs. hydromorphone, 1429
- Carboplatin
 anemia and, erythropoietin for, 1623
 with paclitaxel, for head and neck cancer, 2016
- Carcinoembryonic antigen
 in anorectal melanoma, 18
 in lung cancer, postoperative time-course of, prognosis and, 1533
- Carcinoid heart disease, valvular surgery for, tumor regression after, 605
- Carcinoid tumors
 of esophagus, atypical, 1476
 incidence, metastasis and survival in, 804
 ocreotide for, cholelithiasis and, 830
 of rectum, 1294

- of small intestine, 1086
 - ras* mutations in, 1804
 - Carcinoma. *See* Cancer and specific sites and types
 - Carcinomatosis, peritoneal, in gastric cancer, intraperitoneal hyperthermic chemoperfusion and surgery for, 884
 - Cardiac tumors
 - primary, 1809
 - valvular surgery for, tumor regression after, 605
 - Cardiotoxicity, of dihydro-5-azacytidine, 2237
 - Carmustine
 - for breast cancer, with stem cell transplant, nausea and vomiting after, 1699
 - for multiple myeloma, 1561
 - Cathepsin D, in metastatic breast cancer, 2132
 - CD34, in pre- and postpubertal testicular germ cell tumors, 2430
 - Cell kinetics, in gastric cancer, prognosis and, 226
 - Central nervous system lymphoma, increasing incidence of, 2409
 - Central neurocytoma
 - prognosis in, 790
 - radiation therapy for, 1995
 - Central venous access devices, subcutaneously implanted, 1635
 - Ceramidase, in colorectal cancer, 448
 - C-erb B-2* oncogene, in cervical cancer, cell proliferation and, 513
 - Cerebral metastases
 - in colorectal cancer, long-term survivors of, 1842 (letter)
 - in melanoma, in children, 2440
 - from pediatric solid tumors, 403
 - stereotactic radiosurgery for, 551
 - Cervical cancer
 - all-trans retinoic acid and interferon- α -2a for, 1574
 - c-erb B-2* oncogene in, cell proliferation and, 513
 - clear cell, age peaks in, 2229
 - hormone receptors in, 505
 - hyperthermia and cisplatin for, 935
 - Chemoembolization, in hepatocellular carcinoma with portal vein obstruction, 2087
 - Chemoperfusion, intraperitoneal hyperthermic, for gastric cancer with peritoneal carcinomatosis, 884
 - Chemoresistance, assays for, 1447 (letter)
 - Chemosensitivity
 - assays for, 1447 (letter)
 - retained, in breast cancer, 2137
 - Chemotherapy. *See also generic names of specific drugs*
 - for acute myelogenous leukemia, long-term follow-up for, 1351
 - for advanced urothelial cancer, 110
 - for anal cancer, 2329
 - anemia and, erythropoietin for, 1623
 - antiemesis in, dolasetron for, 1216
 - for breast cancer, 740
 - neutropenia and fever and, 1150
 - pregnancy after, 1271
 - retained sensitivity to, 2137
 - with stem cell transplant, nausea and vomiting after, 1699
 - for central neurocytoma, 790
 - for chronic myeloid leukemia, response to, telomere length and, 1552
 - for colorectal cancer, 1100, 1884
 - with interferon- α , 1094
 - for extrapulmonary small cell carcinoma, 1729
 - for gastric cancer
 - with peritoneal carcinomatosis, 884
 - systemic and intraperitoneal perioperative administration of, 1767
 - gastrointestinal tract metabolic support in, 1794
 - for germ cell tumors
 - residual pulmonary masses after, 345
 - survival after, 161
 - for head and neck cancer, 588, 1394, 2016
 - for hepatocellular carcinoma, with tumor thrombosis of portal vein, 1890
 - for leukemia, 59
 - for mesothelioma, 2237
 - for multiple myeloma, 1561
 - for nasopharyngeal cancer, with radiotherapy, 1279
 - neutropenic fever and, in breast cancer, 1150
 - for non-Hodgkin's lymphoma, 1234
 - for osteosarcoma, 411
 - with lung metastases, 245
 - timing of, 1343
 - for ovarian cancer, glutathione S-transferase- π and glutathione and, 521
 - for pancreatic cancer, with radiotherapy, 1516
 - for pleural mesothelioma, 1897
 - for rectal cancer, with sphincter preservation, 671
 - for recurrent medulloblastoma, 1241
 - rehabilitation after, aerobic exercise in, 1717
 - resistance to, assays for, 1447 (letter)
 - for rhabdomyosarcoma, hepatic venoocclusive disease after, 2435
 - secondary leukemia after, treatment in, 1049
 - sensitivity to
 - assays for, 1447 (letter)
 - retained, 2137
 - subcutaneous central venous access devices for, 1635
 - for testicular germ cell tumors, with bone marrow transplant, 1605
 - for testicular recurrence of acute lymphoblastic leukemia, 2257
 - for uterine cancer, 2391
 - for Wilms' tumor, pulmonary metastases cytodifferentiation in, 1629
- Children. *See also specific cancers of childhood, e.g., Leukemia*
- brain metastases from solid tumors in, 403
 - insular thyroid cancer in, 1044
 - intraoperative electron irradiation for, 2251
 - melanoma in, brain metastases in, 2440

- neuroblastoma in, 2028
 testicular germ cell tumors in, CD34 in, 2430
- Chlorambucil**
 vs. Binet's modified regimen, for chronic lymphocytic leukemia, 2187
 seizures and, 1009
- Cholangiocarcinoma**
 hilar, long-term survival in, 26
 lymph node dissection in, 892
 resectional surgery for, survival and, 185 (letter)
- Cholangiopancreatography, endoscopic retrograde**
 indications for, 1780
 in pregnancy, 1776
- Cholecystokinin**, in gut protection, in chemotherapy, 1794
- Cholelithiasis**, ocreotide and, 830
- Chondrosarcoma**, dedifferentiated, plasminogen activators in, 53
- Choroid sarcoma of bone**, 1903
- Chromogranin**, small intestinal carcinoids and, 1086
- Chromosome 9 aberrations**, familial cancer and, 1527
- Chromosome 17 aberrations**, in pleomorphic adenomas of salivary glands, 2314
- Chronic hepatitis**
 glycyrrhizin in, hepatocellular cancer prophylaxis and, 1494
 hepatocellular clinicopathologic features and, 1509
- Chronic leukemia**. *See* Leukemia
- Cigarette smoking**
 cessation of in relatives of cancer patients, 152
 gastric cancer and, 1840 (letter)
 lung cancer and, in African Americans, 45
 renal cancer and, 2171
- Cirrhosis**
 ethanol injection-treated, recurrent hepatocellular carcinoma and, 1501
 hepatitis C-associated, recurrent hepatocellular carcinoma and, serum alanine aminotransferase and, 688
- Cisplatin**
 for breast cancer, with stem cell transplant, nausea and vomiting after, 1699
 for cervical cancer, 935
 for head and neck cancer, 588, 1394
 for hepatocellular carcinoma, with tumor thrombosis of portal vein, 1890
 for metastatic melanoma, with tamoxifen, 1037
 for osteosarcoma, 411
 for pleural mesothelioma, 1897
 poststorage in vitro cytotoxicity of, 1723
 for uterine cancer, 2391
- c-kit**, in pre- and postpubertal testicular germ cell tumors, 2430
- Clear cell carcinoma**, of vagina and cervix, age peaks in, 2229
- c-met receptor**, in breast tissue, 749
- Cognitive impairment**, in terminal cancer, 835, 1848 (letter)
- Collagen**, type III, N-terminal peptide of, colorectal cancer recurrence and, 1299
- Collagen vascular disease**, radiation toxicity in, 612
- Colon**, carcinoid tumors of, 804
- Colorectal cancer**. *See also* Anal cancer; Rectal cancer
 alkaline sphingomyelinase in, 448
 allelic deletions in, prognosis and, 233
 brain metastases in, long-term survivors of, 1842 (letter)
 clonal divergence in, 1304
 cytokeratin 20-labeled cells in, 1664
 DNA content in, prognosis and, 233, 1304, 2073
 incidence of, by anatomic subtype, 441
 K-ras oncogene in, apoptosis and, 1106
 leucovorin, 5-fluorouracil and interferon- α for, 1094
 in National Cancer Data Base, vs. in SEER program, 2052
 natural killer cells in, prognosis and, 2320
 recurrence of, N-terminal peptide of type III collagen and, 1299
 safflower oil and, 1487
 serum immunoglobulin G1 in, 1482
 staging in, artificial neural networks for, 857
 uracil and tegafur for, 1884
- Common bile duct cancer**, laparoscopic staging of, 1315
- Computed tomography**
 in pancreatic cancer, 1780
 pelvic, in breast cancer, 500
 of retropharyngeal lymphadenopathy, in nasopharyngeal cancer, 869
- Connective tissue disease**, radiation toxicity in, 612
- Cortisone**, with flutamide withdrawal, for prostate cancer, 1964
- Cremophor EL**, paclitaxel and, 1225
- Cryosurgery**, for prostate cancer, 963
- Cutaneous lesions**. *See* Skin
- Cutaneous T-cell lymphoma**, anti-HTLV-1 antibody positive, 269
- Cyclin D1**
 in head and neck cancer, prognosis and, 380
 in transitional cell bladder cancer, 780
- Cyclophosphamide**
 for breast cancer, 740
 with stem cell transplant, nausea and vomiting after, 1699
 dolasetron antiemesis for, 1216
 with doxorubicin, vincristine and prednisone, for chronic lymphocytic leukemia, vs. chlorambucil, 2187
 for multiple myeloma, 1561
 for rhabdomyosarcoma, hepatic venoocclusive disease and, 2435
- Cyclosporin-A**, for hypoplastic myelodysplastic syndrome, 1548
- CYRFA 21-2**, in esophageal cancer, 1647
- Cytokeratin**, in anorectal melanoma, 18
- Cytokeratin 18**, in nonsmall cell lung cancer, prognosis and, 468

- Cytokeratin 20-labeled cells, in colorectal cancer, 1664
 Cytokines. *See also specific cytokines*
 in head and neck cancer, prognosis and, 1401
 hypercalcemia in Richter's syndrome and, 1211
 proinflammatory, cachexia and, 1828
 Cytosine arabinoside
 for acute leukemia, 59
 for acute myelogenous leukemia, long-term follow-up
 for, 1351

D

- Dactinomycin, for rhabdomyosarcoma, hepatic venoocclusive disease and, 2435
 Darwinian theory, clinical relevance of, 2275
 Daunorubicin, for acute myelogenous leukemia, long-term follow-up for, 1351
 Death and dying, cognitive impairment in, 835, 1848 (letter)
 Delirium, in terminal cancer, 835, 1848 (letter)
 Dementia, in terminal cancer, 1848 (letter)
 Depression, in terminal cancer, 1848 (letter)
 Desmoplastic squamous cell carcinoma, of skin and vermilion surface, 915
 Diagnosis, pathologic
 for CNS tumors, consultation for, 796
 as gold standard, 665 (editorial), 796
 Dienogest, for hormone-dependent cancer, 169
 Diet
 in chemotherapy, 1794
 in gut protection, in chemotherapy, 1794
 thyroid cancer and, 2186
 Diffuse pagetoid squamous cell carcinoma in situ, of esophagus, 1865
 Dihydro-5-azacytidine, for mesothelioma, 2237
 DNA content
 in anorectal melanoma, 18
 in colorectal cancer, 233, 1304, 2073
 in endometrial cancer, prognosis and, 944
 in familial epithelial ovarian cancer, 2147
 in myxoid soft tissue tumors, 284
 in oral squamous cell carcinoma, prognosis and, 2309
 in pituitary cancer, 804
 in soft tissue sarcoma, prognosis and, 2371
 DNA mismatch repair, in early-onset gastric cancer, 685
 Dolasetron, as antiemetic, 1216
 Doxorubicin
 for bladder cancer, Fas-mediated cytotoxicity and, 1180
 with cyclophosphamide, vincristine and prednisone, for chronic lymphocytic leukemia, vs. chlorambucil, 2187
 dolasetron antiemesis for, 1216
 hyperthermia and, 214
 for osteosarcoma, 411
 for pleural mesothelioma, 1897
 spermatogenic damage by, leuprolerin protection against, 1014
 for uterine cancer, 2391
 Duodenal cancer, *ras* mutations in, 1804
 Duodenal carcinoid tumors, 1086, 1804
 Dying patients, psychiatric morbidity in, 1848 (letter)
- ## E
- Edema, around bone tumors, prostaglandin and, 255
 eIF4E, in breast cancer, 2385
 Elderly
 colorectal cancer in, uracil and tegafur for, 1884
 glucose metabolism in, tumor necrosis factor- α and, 177
 1111q13 rearrangements, in head and neck cancer, prognosis and, 380
 Emesis
 after chemotherapy and stem cell transplant, in breast cancer, 1699
 dolasetron for, 1216
 Endocrine function, after bone marrow/blood-derived progenitor cell transplant, 1617
 Endocrine therapy. *See also specific agents*
 for breast cancer, 730
 for prostate cancer, pathologic fractures and, 545
 Endometrial cancer
 dienogest for, 169
 keratinocyte growth factor in, 1166
 in premenopausal women, progestin alone for, 320
 S-phase fraction in, prognosis and, 944
 transitional cell, 1933
 Endoscopic retrograde cholangiopancreatography
 indications for, 1780
 in pregnancy, 1776
 Endothelial cell growth factor
 platelet-derived, in bladder cancer, 1190
 vascular, in esophageal cancer, 206
 Enhanced reverse transcriptase-polymerase chain reaction assay, for early prostate cancer, 2402
 Epidermal growth factor, in gut protection, in chemotherapy, 1794
 Epidermal growth factor receptor, in gastric cancer, 1879
 Epipodophyllotoxin-induced acute myeloid leukemia, treatment of, 1049
 Epithelial membrane antigen, in anorectal melanoma, 18
 Epstein-Barr virus infection, concurrent gastric adenocarcinoma and lymphoma and, 1077
 Erectile function, prostate cancer treatment and, 538, 1977
 Erythropoietin, for chemotherapy-related anemia, 1623
 Esophageal cancer
 bcl-2 in, lymph node metastasis and, 1287
 CYRFA 21-2 in, 1647
 laparoscopic staging of, 1315
 p53 in, 425
 squamous cell
 basaloid, 1871
 diffuse pagetoid in situ, 1865
 vascular endothelial growth factor in, 206
 vascularity of, prognosis and, 220

Esophageal carcinoids, atypical, 1476
 Estrogen receptors, in cervical adenocarcinoma, 505
 Ethanol injection, percutaneous, in cirrhosis, recurrent hepatocellular carcinoma after, 1501
 Ethical standards, for research reports, 626 (letter)
 Etoposide, for epipodophyllotoxin-induced acute myeloid leukemia, 1049
 Eukaryotic initiation factor 4E, in breast cancer, 2385
 Evolutionary theory, clinical relevance of, 2275
 Ewing's sarcoma, brain metastases in, 403
 Exercise, aerobic, after chemotherapy and peripheral stem cell transplant, 1717
 Exponential survival trees method, for melanoma classification, 1122
 Extramedullary acute promyelocytic leukemia, 2263 (letter)
 Extraovarian müllerian adenocarcinoma, vs. primary ovarian cancer, 1587
 Extrapulmonary small cell carcinoma, 1729

F

Factor V Leiden, tamoxifen-related venous thrombosis and, 2024
 Familial cancer, chromosome 9 aberrations and, 1527
 Familial epithelial ovarian cancer, p53 and HER-2/*neu* in, 2147
 Fas/APO-1/CD95, on gastric cancer, 433
 Fatigue, after chemotherapy, aerobic exercise for, 1717
 Fatty acids, in gut protection, in chemotherapy, 1794
 Federal government, managed health care and, 656
 Fertility, in breast cancer survivors, 1271
 Fever, in chemotherapy, for breast cancer, 1150
 Fiber, in gut protection, in chemotherapy, 1794
 Fibroblast growth factor receptor-2, in endometrial cancer, 1166
 Fine-needle aspiration biopsy, in pancreatic cancer, 1780
 FISH analysis, of myxoid soft tissue tumors, 284
 Flow cytometry. *See* DNA content
 Fluorescence in situ hybridization analysis, of myxoid soft tissue tumors, 284
 18-Fluorodeoxyglucose, survival and, 115
 18-Fluorodeoxyglucose positron emission tomography of glioma, prognosis and, 115
 in pancreatic cancer, prognosis and, 695
 5-Fluorouracil
 for breast cancer, 740
 for colorectal cancer, with leucovorin, 1100
 and with interferon- α , 1094
 for gastric cancer, apoptosis and, 12
 for head and neck cancer, 588, 1394
 for hepatocellular carcinoma, with tumor thrombosis of portal vein, 1890
 for pancreatic cancer, with radiotherapy, 1516
 Flutamide withdrawal, for prostate cancer, 1964
 Follicular dendritic cell sarcoma, malignant potential of, 294
 Fractures, luteinizing hormone-releasing hormone agonists and, in prostate cancer, 545
 France, gliomas in, descriptive epidemiology of, 1195

α -1,3-Fucosyltransferase, sialy Lewis^x synthesis and, in lung cancer, 1678

Functional Assessment of Cancer Therapy-General, psychometric assessment of, 2446

G

Gallbladder cancer
 lymph node dissection in, 892
 resectional surgery for, survival and, 185 (letter)
 Gallium nitrate, for advanced urothelial cancer, 110
 Gallstones, ocreotide and, 830
 Gangliogliomas, in adults, 127
 Ganglioma, ultrastructure and immunohistochemistry of, 989
 Garlic, for bladder cancer, 1987
 Gastric cancer
 adenocarcinoma, with concurrent gastric lymphoma, 1077
 advanced, p21 in, survival and, 2067
 alcohol and, 1840 (letter)
 apoptosis in, 5-fluorouracil and, 12
 apoptosis receptors on, 433
 cell kinetics in, prognosis and, 226
 chemotherapy for, preoperative systemic and postoperative intraperitoneal administration of, 1767
 early onset, microsatellite instability in, 685
 epidermal growth factor receptor in, 1879
 gene amplification in, prognosis and, 226
 green tea and, 1840 (letter)
 nodal micrometastases in, 1069
 peritoneal carcinomatosis in, intraperitoneal hyperthermic chemoperfusion and surgery for, 884
 plasminogen activator inhibitor-1 in, prognosis and, 878
 smoking and, 1840 (letter)
 urokinase-type plasminogen activator in, prognosis and, 878
 Gastric lymphoma
 with concurrent gastric adenocarcinoma, 1077
H. pylori and, 3
 vs. lymph node disease, 390
 Gastric pseudolymphoma, reclassification of, 1656
 Gastrointestinal tract metabolic support, in chemotherapy, 1794
 Gastrointestinal tumors, laparoscopic staging of, 1315
 Gender, astrocytoma prognosis and, 370
 Gene amplification, in gastric cancer, prognosis and, 226
 Genetic algorithm neural network, vs. logistic regression, for nonsmall cell cancer survival, 1338
 Genetic susceptibility testing, for breast cancer
 reactions to, 2219
 utility of, 2063, 2066 (editorials)
 Germ cell tumors
 in children, brain metastases in, 403
 extragonadal, histogenesis of, 1031
 intracranial, spontaneous regression of, 558
 mediastinal
 chemotherapy for, survival after, 161
 with concurrent testicular germinoma, 1031

- testicular. *See also* Testicular cancer
 chemotherapy for
 with bone marrow transplant, 1605
 residual pulmonary masses after, 345
 survival after, 161
 low stage, prognostic factors in, 1641, 1646 (editorials), 1710
 MIB-1 in, metastasis risk and, 1641, 1645, 1710
 p53, *c-kit* and CD34 in, in pre- and postpubertal males, 2430
 Gleason score, in prostate cancer, prognosis and, 1370, 2154
 Glioblastoma
 classification and grading of, 1381
 descriptive epidemiology of, in France, 1195
 proliferation index in, prognosis and, 849
 Glioma(s)
 classification and grading of, 1381
 descriptive epidemiology of, in France, 1195
 18-fluorodeoxyglucose uptake by, survival and, 115
 proliferation index in, prognosis and, 849
 Glucagon-like peptide 2, in gut protection, in chemotherapy, 1794
 Glucose-induced thermogenesis, tumor necrosis factor- α and, in elderly, 177
 Glutamine, in gut protection, in chemotherapy, 1794
 Glutathione, in ovarian cancer, chemotherapy and, 521
 Glutathione S-transferase
 in osteosarcoma, prognosis and, 2336
 in ovarian cancer, 521
 chemotherapy and, 521
 in prostate cancer, 1595
 Glycyrrhizin, in chronic hepatitis, hepatocellular cancer prophylaxis and, 1494
 Gonadal function, after bone marrow/blood-derived progenitor cell transplant, 1617
 Government, managed health care and, 656
 Granulosa cell tumor of ovary, prognostic factors in, 1951
 Green tea, gastric cancer and, 1840 (letter)
 Growth factors, in gut protection, in chemotherapy, 1794
 Growth hormone, in gut protection, in chemotherapy, 1794
 Gut protection, in chemotherapy, 1794

H

- Head and neck cancer
 chemotherapy for, anemia and, erythropoietin for, 1623
 chromosomal abnormalities in, prognosis and, 380
 cisplatin and 5-fluorouracil for, 588
 cyclin D1 in, prognosis and, 380
 human papillomavirus in, 595
 interleukin-2 receptor in, prognosis and, 1401
 membrane type 1-matrix metalloproteinase in, 139
 p21^{Waf1/Cip1} cyclin-dependent kinase inhibitor gene in, 2424
 paclitaxel with carboplatin for, 2016
 vinorelbine, cisplatin and 5-fluorouracil for, 1394

- Heart. *See under* Cardiac
 Heat shock protein 27, in osteosarcoma, prognosis and, 2336
Helicobacter pylori infection
 concurrent gastric adenocarcinoma and lymphoma and, 1077
 gastric lymphoma and, 3
 Hepatectomy, cancer recurrence after, hepatitis virus serologic status and, 1509
 Hepatic cirrhosis
 ethanol injection-treated, recurrent hepatocellular carcinoma and, 1501
 hepatitis C-associated, recurrent hepatocellular carcinoma and, serum alanine aminotransferase and, 688
 Hepatic venoocclusive disease, after chemotherapy for rhabdomyosarcoma, 2435
 Hepatitis C-associated cirrhosis, recurrent hepatocellular carcinoma in, serum alanine aminotransferase and, 688
 Hepatitis C-associated hepatocellular carcinoma, glycyrrhizin prophylaxis for, 1494
 Hepatitis C-associated hepatocellular carcinoma, postoperative recurrence of, 1509
 Hepatocellular carcinoma
 hepatitis C-associated, glycyrrhizin prophylaxis for, 1494
 hepatitis C-associated, postoperative recurrence of, 1509
 laparoscopic staging of, 1315
 with portal vein obstruction
 chemotherapy for, 1890
 transcatheter arterial chemoembolization for, 2087
 recurrent
 in cirrhotic patients treated by ethanol injection, 1501
 hepatitis C serologic status and, 1509
 serum alanine transferase and, 688
 vinyl chloride and, 1671
 HER-2/*neu*
 in extraovarian müllerian adenocarcinoma vs. primary ovarian cancer, 1587
 in familial epithelial ovarian cancer, 2147
 in prostate cancer, prognosis and, 2162
 Hilar cholangiocarcinoma, long-term survival in, 26
 Hiroshima atomic bomb survivors, salivary gland tumors in, 1465
 HMOs. *See* Managed health care
 Hodgkin's disease
 radiation therapy for, 145
 stage I and II, late relapse in, 1422
 in young adults, increasing incidence of, 2209
 Hormonal therapy. *See also specific agents*
 for breast cancer, 730
 for prostate cancer, 1964
 pathologic fractures and, 545
 Hormone receptors, in cervical adenocarcinoma, 505
 HTLV-1, cutaneous T-cell lymphoma and, 269

- Human immunodeficiency virus infection, cancer incidence in, 1004
- Human papillomavirus, in Bowen's disease of hands, 1911
- Human papillomavirus-associated cancer
of head and neck, 595
of paranasal sinuses, 1321
- Human papillomavirus-associated cancer, interferon and tumor necrosis factor- α for, 924
- Hydrocortisone, with flutamide withdrawal, for prostate cancer, 1964
- Hydromorphone, vs. oxycodone, for pain, 1429
- Hypercalcemia, in Richter's syndrome, 1211
- Hypermetabolism, in nonsmall cell lung cancer, 717
- Hyperparathyroidism, thyroid cancer and, 1611
- Hypertension, renal cancer and, 2171
- Hyperthermia
for cervical cancer, 935
doxorubicin and, 214
- Hyperthermic chemoperfusion, for peritoneal carcinomatosis in gastric cancer, 884
- Hyponatremia, in small cell lung cancer, ectopic atrial natriuretic peptide and, 35
- Hypoplastic myelodysplastic syndrome, immunosuppressive therapy for, 1548
- Hypothyroidism, after bone marrow/blood-derived progenitor cell transplant, 1617

I

- Idarubicin, for prostate cancer, 1703
- Ifosfamide
for advanced urothelial cancer, 110
for osteosarcoma, 411
- Ileal cancer, *ras* mutations in, 1804
- Ileal carcinoid tumors, 1086, 1804
- Immune response, suppression of, in HPV-associated cancers
- Immunoglobulin G1, in colorectal cancer, 1482
- Immunosuppressive therapy, for hypoplastic myelodysplastic syndrome, 1548
- Immunotherapy. *See also specific agents*
for colorectal cancer, 1094
for melanoma, sialyl Lewis antigens and, 1686
- Impotence, prostate cancer treatment and, 538, 1977
- Infertility, in breast cancer survivors, 1271
- Insular thyroid cancer, in adolescents, 1044
- Insulin-like growth factor, in gut protection, in chemotherapy, 1794
- Interferon
for HPV-associated cancers, 924
for melanoma, 1843 (letter)
- Interferon- α
for colorectal cancer, with leucovorin and 5-fluorouracil, 1094
for melanoma, 2354
- Interferon- α -2a, for cervical cancer, 1574
- Interleukin-2 liposome inhalation therapy, for pulmonary metastases, 1409
- Interleukin-2 receptor, in head and neck cancer, prognosis and, 1401
- Interleukin-6
in head and neck cancer, prognosis and, 1401
hypercalcemia in Richter's syndrome and, 1211
- Interleukin-11, in gut protection, in chemotherapy, 1794
- International Study Group findings, on multigene effects, 416
- International Union Against Cancer
Committee on International Collaborative Activities,
Workshop on Development of European Cancer
Data Base, 1248
World Conference for Cancer Organisations, 619
- Intestinal type gastric cancer, apoptosis receptors in, 433
- Intracranial germinoma, spontaneous regression of, 558
- Intraductal papillary mucinous tumors of pancreas, *K-ras* mutations in, 900
- Intraoperative electron irradiation, for pediatric malignancies, 2251
- Intraperitoneal hyperthermic chemoperfusion, for gastric cancer with peritoneal carcinomatosis, 884
- Inverted papilloma of paranasal sinus, p53 and HPV and, 1321
- Iodine-131, optimum dose of, for thyroid remnant ablation, 190 (letter)
- Islet cell tumors, ocreotide for, cholelithiasis and, 830

J

- Japan
neuroblastoma cell line in, from mass screening, 2036
prostate specific antigen density in, diagnostic utility of, 1969
- Jejunal cancer, *ras* mutations in, 1804
- Jejunal carcinoid tumors, 1086, 1804

K

- K-12 *ras* mutations, in duodenal cancer, 1804
- Keratinocyte growth factor, in endometrial cancer, 1166
- Ki-67
in ganglioma, prognosis and, 989
in prostate cancer, postoperative recurrence and, 952
- Kidney
primitive neuroectodermal tumor of, 2243
renal cell carcinoma of
multifocal, cytogenetics, histopathology and immunology of, 9758
thyroid metastases in, 574
transitional cell carcinoma of, p53 and, 2178
- Wilms' tumor of
brain metastases in, 403
pulmonary metastases with, cytodifferentiation of, 1629
- Kidney cancer, prognostic factors in, 2171
- Klatskin's tumor, long-term survival for, 26
- K-ras*
in colorectal cancer, apoptosis and, 1106
in intraductal papillary mucinous tumors of pancreas, 900

- in mucinous ovarian tumors, 1581
in nonsmall cell lung cancer, prognosis and, 462
- L**
- Laparoscopic staging
 of pancreatic cancer, 1315, 1780
 of upper gastrointestinal tumors, 1315, 1780
- Large intestine. *See under* Colon; Colorectal; Rectal
- Laryngeal cancer, squamous cell, *bcl-1/cyclin D1* gene in, 1114
- Leiomyoma, of thyroid, 579
- Leiomyosarcoma, of thyroid, 579
- Leucovorin, for colorectal cancer
 with 5-fluorouracil, 1100
 and with interferon- α , 1094
 with uracil and tegafur, 1884
- Leukemia
 acute, cytosine arabinoside and mitoxantrone for, 59
 acute lymphoblastic
 age peak in, socioeconomic status and, 2045
 testicular recurrence of, treatment of, 2257
 acute myelogenous, daunorubicin, vincristine and cytosine for, long-term follow-up for, 1351
 acute myeloid, epipodophyllotoxin-induced, treatment of, 1049
 acute promyelocytic, extramedullary, 2263 (letter)
 chronic lymphocytic, chlorambucil vs. Binet's modified regimen for, 2107
 chronic myeloid, telomere length and cytogenetic response in, 1552
- Leuporelin, protective effect against doxorubicin-induced spermatogenic damage, 1014
- Liposarcoma, myxoid, fluorescence in situ hybridization analysis of, 284
- Liver. *See also under* Hepatic and related entries
 venocclusive disease of, after chemotherapy for rhabdomyosarcoma, 2435
- LN-2, in malignant fibrous histiocytoma vs. atypical fibroxanthoma, 2115
- Lozenge, antibiotic, for radiation mucositis, 2193
- Lumpectomy
 for early stage I-II synchronous bilateral cancer, 1362
 margins in, 1453, 1459 (editorials), 1568
 race and socioeconomic status and, 314
 recurrence after, calcifications and, 1355
- Lung cancer
 in African Americans, smoking and, 45
 with atypical adenomatous hyperplasia, prognosis of, 1521
 histologic trends in, in Switzerland, 906
 lymphocyte primary chromosome 9 aberrations and, 1527
 in National Cancer Data Base, vs. in SEER program, 2052
 nonsmall cell
 autologous tumor killing activity in, prognosis and, 474
 cytokeratin 18 in, prognosis and, 468
 K-ras mutation in, prognosis and, 462
 paclitaxel for, 724
 pre- and postoperative energy balance in, 717
 retinoblastoma protein in, 1329
 survival in, genetic algorithm neural network prediction of, 1338
 postoperative carcinoembryonic antigen time-course in, prognosis and, 1533
 sialyl Lewis^x synthesis in, α -1,3-fucosyltransferase and α -2,3-sialyltransferase and, 1678
 small cell, ectopic atrial natriuretic peptide in, 35
- Lung metastases
 from germ cell tumors, postchemotherapy residua of, 345
 interleukin-2 liposome inhalation therapy for, 1409
 in osteosarcoma, chemotherapy for, 245
 in Wilms' tumor, cytodifferentiation of, 1629
- Lung resistance-related protein, in osteosarcoma, prognosis and, 2336
- Lupus erythematosus, radiation toxicity in, 612
- Luteinizing hormone-releasing hormone agonists, for prostate cancer, pathologic fractures and, 545
- Lymphadenopathy, retropharyngeal, in nasopharyngeal cancer, computed tomography of, 869
- Lymph node dissection, in gallbladder cancer, 892
- Lymph node metastasis
 axillary, in T1 breast cancer, predictors of, 1918
 in breast cancer, prediction of, 1856, 1862 (editorials)
 in esophageal cancer, *bcl-2* and, 1287
 occult, in gastric cancer, 1069
 in oral squamous cell carcinoma, DNA content and, 2309
- Lymphocyte primary chromosome 9 aberrations, familial cancer and, 1527
- Lymphoma
 adult T-cell leukemia/lymphoma, vs. cutaneous T-cell lymphoma, HTLV-1 and, 269
 central nervous system, increasing incidence of, 2409
 cutaneous T-cell, anti-HTLV-1 antibody positive, 269
 extranodal marginal zone B-cell, gastric pseudo-lymphoma as, 1656
 gastric
 with concurrent gastric adenocarcinoma, 1077
 H. pylori and, 3
 vs. lymph node disease, 390
 Hodgkin's. *See* Hodgkin's disease
 MALT
 gastric, 1656
 vs. lymph node disease, 390
 pregnancy-associated, 191 (letter)
 proMACE-Cyta-BOM for, 1234
- M**
- Magnetic resonance imaging, of peritumoral edema, 255
- Malignant fibrous histiocytoma
 of bone, clinicopathology of, 482
 LN-2 in, vs. in atypical fibroxanthoma, 2115
- Malignant gliomas of childhood, proliferation index in, prognosis and, 849

- Malignant islet cell tumors, ocreotide for, cholelithiasis and, 830
- Malignant lymphoma. *See* Lymphoma
- Malignant melanoma. *See* Melanoma
- Malignant mesothelioma
- after radiation therapy, 192 (letter)
 - dihydro-5-azacytidine for, 2237
 - pleural, cisplatin, doxorubicin and mitomycin for, 1897
- MALT, gastric pseudolymphoma and, 1656
- MALT lymphoma
- gastric, 1656
 - vs. lymph node disease, 390
- Mammography
- mortality rates and, 1 (editorial), 69
 - risk-benefit analysis for, 628 (letter)
 - in younger women, survival and, 1923
- Managed health care
- future of, 661
 - government and, 656
 - overview of, 648
 - professional organizations and, 653
- Managed Health Care Conference (ACS), Feb. 1 supplement
- Mastectomy
- vs. breast-conserving surgery, race and socioeconomic status and, 314
 - radiation therapy after, 669, 1061, 1067 (editorial)
 - silicone implants after, health implications of, 1747
- Matrix metalloproteinase, in head and neck cancer, 139
- MDM2, in osteosarcoma, 1541
- mdm-2, in pancreatic cancer, 700
- Mediastinal germ cell tumors
- chemotherapy for, survival after, 161
 - with concurrent testicular germinoma, 1031
- Medullary thyroid cancer. *See also* Thyroid cancer
- prognosis in, 132
- Medulloblastoma, recurrent, treatment of, 1241
- Megestrol acetate, for breast cancer, vs. anastrozole, 730
- Melanoma
- anorectal, 18
 - brain metastases in, in children, 2440
 - cutaneous, ultra-late recurrence of, 2361
 - disseminated, prolonged survival in, 2345
 - interferon for, 1843 (letter), 2354
 - localized, classification of, 1122
 - metastatic, tamoxifen and cisplatin for, 1037
 - prognostic factors in, in Sweden, 275
 - in sarcoma, 843
 - sialyl Lewis^x and sialyl Lewis^a in, 1686
 - tyrosine autoantibodies in, 1461
 - of unknown primary site, clinical behavior and etiology of, 1816
 - uveal, nucleolar size in, prognosis and, 982
- Melphalan
- for multiple myeloma, 1561
 - with tumor necrosis factor- α , via isolated limb perfusion for, for soft tissue sarcoma, 1129
- Membrane type 1-matrix metalloproteinase, in head and neck cancer, 139
- Meningioma, secretory, 2003
- Mental status, in terminal cancer, 835
- Mesothelioma
- after radiation therapy, 192 (letter)
 - dihydro-5-azacytidine for, 2237
 - pleural, cisplatin, doxorubicin and mitomycin for, 1897
- Metabolic changes, glucose-related, tumor necrosis factor- α and, in elderly, 177
- Metabolic support, gastrointestinal, in chemotherapy, 1794
- Metallothioneines, in osteosarcoma, prognosis and, 2336
- Metastasis
- brain
 - in colorectal cancer, long-term survivors of, 1842 (letter)
 - in melanoma, in children, 2440
 - from pediatric solid tumors, 403
 - stereotactic radiosurgery for, 551 - from carcinoid tumors, 804
 - from melanoma of unknown primary site, 1816
 - nodal
 - in breast cancer, prediction of, 1856, 1862 (editorials)
 - in esophageal cancer, *bcl-2* and, 1287
 - occult, in gastric cancer, 1069
 - in oral squamous cell carcinoma, DNA content and, 2309
 - in T1 breast cancer, predictors of, 1918 - in pituitary cancer, 804
 - pulmonary
 - from germ cell tumors, postchemotherapy residua of, 345
 - interleukin-2 liposome inhalation therapy for, 1409
 - in osteosarcoma, chemotherapy for, 245
 - in Wilms' tumor, cytodifferentiation of, 1629 - thyroid, 574
- Methotrexate
- for breast cancer, 740
 - for osteosarcoma, 411
 - for uterine cancer, 2391
- MIB-1, in testicular germ cell tumors, metastasis risk and, 1641, 1645, 1710
- MIB-1 index, in malignant gliomas of childhood, 849
- Micronutrients, thyroid cancer and, 2186
- Microsatellite instability, in early-onset gastric cancer, 685
- Mini-Mental State Examination, in terminal cancer, 835
- Mitomycin, for pleural mesothelioma, 1897
- Mitoxantrone
- for acute leukemia, 59
 - for breast cancer, 740
- Mixed connective tissue disease, radiation toxicity in, 612
- Monoclonal antibodies, anti-Fas, in bladder cancer, doxorubicin and, 1180
- Monosomy 7 myelodysplastic syndrome, in neurofibromatosis type 1, 1438
- Mouth. *See under* Oral

Mucosa-associated lymphoid tissue. *See under* MALT
 Mucositis, radiation, antibiotic lozenge for, 2193
 Multidisciplinary breast cancer clinics, 2380
 Multigene effects, International Study Group findings on, 416
 Multiple myeloma, chemotherapy for, 1561
 Myelodysplastic syndrome(s)
 Behcet's syndrome with, 262
 hypoplastic, immunosuppressive therapy for, 1548
 in neurofibromatosis type 1, 1438
 Myeloma, chemotherapy for, 1561
 Myxoid chondrosarcoma, of bone, 1903
 Myxoid liposarcoma, fluorescence in situ hybridization analysis of, 284
 Myxoma, atrial, 1809

N

Nagasaki atomic bomb survivors, salivary gland tumors in, 1465
 Nasopharyngeal cancer
 advanced, chemotherapy plus radiotherapy vs. radiotherapy alone for, 1279
 retropharyngeal lymphadenopathy in, computed tomography of, 869
 National Cancer Advisory Board, 25-year retrospective on, 2269 (letter)
 National Cancer Data Base, breast, colorectal, lung and prostate cancers in, vs. in SEER program, 2052
 Natural killer cells, in colorectal cancer, prognosis and, 2320
 Nausea and vomiting
 after chemotherapy and stem cell transplant, in breast cancer, 1699
 dolasetron for, 1216
 Neovascularization, in esophageal cancer
 prognosis and, 220
 vascular endothelial growth factor and, 206
 Nephroblastoma
 brain metastases in, 403
 pulmonary metastases with, cytodifferentiation of, 1629
 Nephrotic syndrome, chlorambucil-induced seizures in, 1009
 Neuroblastoma
 in adults and adolescents, 2028
 brain metastases in, 403
 cell line for, from mass screening, 2036
 immunobiology of, in mice vs. humans, 1757
 Neurofibromatosis type 1
 malignant tumors in, 2125
 monosomy 7 myelodysplastic syndrome in, 1438
 Neuropathology consultation, benefits of, 796
 Neurotensin, in gut protection, in chemotherapy, 1794
 Neutropenia, in chemotherapy, for breast cancer, 1150
 nm23, in breast cancer, metastatic potential and, 1158
 Nodes. *See* Lymph nodes
 Non-Hodgkin's lymphoma. *See* Lymphoma
 Nonpeptide neurotensin receptor antagonist SR48692, for neurotensin-induced pancreatic cancer, 1787
 N-terminal peptide of Type III procollagen, colorectal cancer recurrence and, 1299
 Nucleolar organizer regions
 in oral squamous cell carcinoma, 2200
 in prostate cancer, 1956
 Nutrients, in gut protection, in chemotherapy, 1794
 Nutrition, thyroid cancer and, 2186
 Nutritional support, for cachexia, 1828

O

Obituaries
 Maurice M. Black, 203
 Oscar Auerbach, 1853
 Oil, safflower, colorectal carcinogenesis and, 1487
 Oleic acid, colorectal carcinogenesis and, 1487
 Oligoastrocytoma
 classification and grading of, 1381
 supratentorial WHO grade 2, prognostic factors for, 370
 Oligodendroglioma
 classification and grading of, 1381
 descriptive epidemiology of, in France, 1195
 Oncogene amplification, in gastric cancer, prognosis and, 226
 OOS-A regimen, for osteosarcoma, 411
 Oral squamous cell carcinoma
 DNA flow cytometry for, prognosis and, 2309
 nucleolar organizer regions in, 2200
 Osteoporosis, luteinizing hormone-releasing hormone agonists and, in prostate cancer, 545
 Osteosarcoma
 brain metastases in, 403
 chemotherapy for
 with lung metastases, 245
 neoadjuvant, 411
 timing of, 1343
 MDM2 in, 1541
 melanoma in, 843
 overexpression of resistance-related proteins in, prognosis and, 2336
 p53 in, 1541
 small cell, 2095
 Ovarian cancer
 advanced, paclitaxel for, 2264 (letter)
 vs. extraovarian müllerian adenocarcinoma, 1587
 familial epithelial, p53 and HER-2/*neu* in, 2147
 glutathione S-transferase- π and glutathione in, chemotherapy and, 521
 granulosa cell tumor, prognostic factors in, 1951
 mucinous, K-*ras* in, 1581
 perineal talc exposure and, 2396
 progesterone in, apoptosis and p53 in, 1944
 Oxycodone, vs. hydromorphone, for pain, 1429

P

p21, in advanced gastric cancer, survival and, 2067
 p21/WAF-1, in pancreatic cancer, 700
 p21^{Waf1/Cip1} cyclin-dependent kinase inhibitor gene, in prostate cancer and head and neck cancer, 2424

- p53
 in esophageal cancer, 425
 in extraovarian müllerian adenocarcinoma vs. primary ovarian cancer, 1587
 in familial epithelial ovarian cancer, 2147
 in ganglioma, 989
 in gastric cancer, 433
 in non-small cell lung cancer, retinoblastoma protein and, 1329
 in osteosarcoma, 1541
 in ovarian cancer, progesterone and, 1944
 in pancreatic cancer, 700
 in paranasal sinus cancer, 1321
 in pituitary cancer, 804
 in pleomorphic adenomas of salivary glands, 2314
 in pre- and postpubertal testicular germ cell tumors, 2430
 in prostate cancer, postoperative recurrence and, 952
 in transitional cell carcinoma of renal pelvis and ureter, 2178
- Paclitaxel
 for advanced ovarian cancer, 2264 (letter)
 anemia and, erythropoietin for, 1623
 cremophor EL and, 1225
 for head and neck cancer, with carboplatin, 2016
 for non-small cell lung cancer, 724
 radioimmunoassays for, 1022
 skin ulceration and, 2266 (letter)
- Pagetoid squamous cell carcinoma in situ, of esophagus, 1865
- Pain, oxycodone for, vs. hydromorphone, 1429
- Pancreatic cancer
 diagnostic workup for, 1780
 peroral pancreatoscopy and pancreatoscopic cytology in, 454
¹⁸F-fluorodeoxyglucose positron emission tomography in, prognosis and, 695
 5-fluorouracil for, with radiotherapy, 1516
 laparoscopic staging of, 1315, 1780
 management of, 626 (letter)
 neurotensin-induced, nonpeptide neurotensin receptor antagonist SR48692 for, 1787
 p53, mdm-2 and p21/WAF-1 in, 700
 in pregnancy, 1776
- Pancreatic tumors, intraductal papillary mucinous, K-ras mutations in, 900
- Pancreatoscopic cytology, 454
- Pancreatoscopy, peroral, 454
- Paragangliomas, pigmented extraadrenal, 398
- Paranasal sinus cancer, HPV and p53 in, 1321
- Parathormone-related peptide, hypercalcemia in Richter's syndrome and, 1211
- Parenteral nutrition, for cachexia, 1828
- Pathologic diagnosis
 for CNS tumors, consultation for, 796
 as gold standard, 665 (editorial), 796
- Pathologic fractures, luteinizing hormone-releasing hormone agonists and, in prostate cancer, 545
- Pediatric cancer. *See* Children and specific cancers of childhood, e.g., Leukemia
- Pelvic computed tomography, in breast cancer, 500
- Peptides, in gut protection, in chemotherapy, 1794
- Percutaneous ethanol injection, in cirrhosis, recurrent hepatocellular carcinoma after, 1501
- Periampullary tumors, laparoscopic staging of, 1315
- Perineal talc exposure, ovarian cancer and, 2396
- Peripheral nerve sheath tumors, melanoma in, 843
- Peripheral stem cell transplant
 for breast cancer, with chemotherapy, nausea and vomiting after, 1699
 endocrine function and bone metabolism after, 1617
 rehabilitation after, aerobic exercise in, 1717
- Peritoneal carcinomatosis, in gastric cancer, intraperitoneal hyperthermic chemoperfusion and surgery for, 884
- Peritumoral edema, in bone tumors, prostaglandin and, 255
- Photodynamic therapy, 5-aminolevulinic acid-based, 2282
- Pigmented extraadrenal paragangliomas, 398
- Pituitary cancer, clinicopathology and prognosis of, 804
- Plasminogen activator inhibitor-1
 in dedifferentiated chondrosarcoma, 53
 in gastric cancer, prognosis and, 878
- Plasminogen activators, in dedifferentiated chondrosarcoma, 53
- Platelet-derived endothelial cell growth factor, in bladder cancer, 1190
- Pleomorphic adenomas, of salivary glands, p53 and chromosome 17 aberrations in, 2314
- Pleural mesothelioma, cisplatin, doxorubicin and mitomycin for, 1897
- Ploidy. *See* DNA content
- Port, subcutaneous, 1635
- Portal vein obstruction
 after chemotherapy for rhabdomyosarcoma, 2435
 in hepatocellular carcinoma
 chemotherapy and, 1890
 transcatheter arterial chemoembolization for, 2087
- Positron emission tomography, 18-fluorodeoxyglucose for glioma, prognosis and, 115
 in pancreatic cancer, prognosis and, 695
- Poverty
 age peak in acute lymphoblastic leukemia and, 2045
 breast-conserving surgery and, 314
- Pregnancy
 in breast cancer survivors, 1271
 lymphoma in, 191 (letter)
 pancreatic cancer in, 1776
- Primitive neuroectodermal tumor, of kidney, 2243
- Professional organizations, managed health care and, 653
- Progenitor cell transplant
 for breast cancer, with chemotherapy, nausea and vomiting after, 1699
 endocrine function and bone metabolism after, 1617

- Progesterone, in ovarian cancer, apoptosis and p53 in, 1944
- Progesterone receptors, in cervical adenocarcinoma, 505
- Progestin, for endometrial cancer, in premenopausal women, 320
- Prognosis. *See also specific prognostic factors and cancers*
artificial neural networks and, 857
- Proliferation index, in malignant gliomas of childhood, 849
- ProMACE-Cyta-BOM, for non-Hodgkin's lymphoma, 1234
- Prostate cancer, surgery for. *See Prostatectomy*
- Prostaglandin, in bone tumors, peritumoral edema and, 255
- Prostate cancer
age and, 99
angiogenesis in, prognosis and, 772
cryosurgery for, 963
declining incidence of, 188 (letter)
enhanced reverse transcriptase-polymerase chain reaction assay for, 2402
erectile dysfunction and, 538
flutamide withdrawal plus hydrocortisone for, 1964
free to total prostate specific antigen ratio in, 90
Gleason score in, prognosis and, 1370, 2154
glutathione S-transferase in, 1595
HER-2/*neu* in, prognosis and, 2162
hormone therapy for, pathologic fractures and, 545
idarubicin for, 1703
incidence trends in, 99
localized
enhanced prognostic system for, 2154
prognostic factors for, 1370
in National Cancer Data Base, vs. in SEER program, 2052
p21^{Waf1/Cip1} cyclin-dependent kinase inhibitor gene in, 2424
with perineural invasion, radiation therapy and, 75
postoperative recurrence of, predictive model for, 952
prognostic factors in, 328, 337, 1956
prostate specific antigen in. *See Prostate specific antigen*
prostatic intraepithelial neoplasia and, 1172
quality of life after, 1977
race and, 99
radiotherapy for
biopsy after, 81
bladder cancer and other second malignancies after, 1600
erectile dysfunction and, 538
with perineural invasion, 75
predictive factors for, 328, 337
quality of life after, 1977
staging nomogram for, 529
T classification in, prognosis and, 1370
- Prostatectomy
quality of life after, 1977
radical, erectile dysfunction and, 538
recurrence after, predictive model for, 952
- Prostate specific antigen
doubling time of, idarubicin and, 1703
free to total ratio of, 90
prostate volume and, 104
prognosis and, 1370, 2154
radiotherapy results and, 328, 337
- Prostate specific antigen density, diagnostic utility of, 1969
- Prostatic intraepithelial neoplasia, in surgical resections, 1172
- Pseudolymphoma, gastric, reclassification of, 1656
- Psychiatric morbidity, in terminal cancer, 1848 (letter)
- Psychometric assessment, of Functional Assessment of Cancer Therapy-General, 2446
- Pulmonary metastasis
from germ cell tumors, postchemotherapy residua of, 345
interleukin-2 liposome inhalation therapy for, 1409
in osteosarcoma, chemotherapy for, 245
in Wilms' tumor, cytodifferentiation of, 1629
- Q**
- Quality of life, after prostate cancer treatment, 1977
- R**
- Race
breast-conserving surgery and, 314
colorectal adenocarcinoma and, 441
lung cancer and, 45
prostate cancer and, 99
- Radiation exposure, salivary gland tumors and, 1465
- Radiation necrosis, vs. glioma recurrence, 18-fluoro-deoxyglucose PET for, 115
- Radiation therapy
for anal cancer, with/without chemotherapy, 2329
for bone marrow transplant, late effects of, 1617
for breast cancer, 669, 1138
for central neurocytoma, 790, 1995
for cervical cancer, hyperthermia and cisplatin after, 935
for extrapulmonary small cell carcinoma, 1729
for Hodgkin's disease, 145
breast cancer after, 1203
intraoperative electron irradiation, for pediatric malignancies, 2251
malignant mesothelioma after, 192 (letter)
mucositis and, antibiotic lozenge for, 2193
for nasopharyngeal cancer, with/without chemotherapy, 1279
for pancreatic cancer, with 5-fluorouracil, 1516
postmastectomy, 669, 1061, 1067 (editorial)
for prostate cancer
biopsy after, 81
bladder cancer and other second malignancies after, 1600
erectile dysfunction and, 538, 1977

- with perineural invasion, 75
- predictive factors for, 328, 337
- for rectal cancer, with sphincter preservation, 671
- for testicular recurrence of acute lymphoblastic leukemia, 2257
- toxicity of, in mixed connective tissue disease, 612
- for Wilms' tumor, pulmonary metastases cytodifferentiation in, 1629
- Radical prostatectomy
 - erectile dysfunction and, 538
 - recurrence after, predictive model for, 952
- Radioimmunassays, for paclitaxel, 1022
- Radiosurgery, stereotactic, for brain metastases, 551
- ras* mutations, in duodenal cancer, 1804
- ras* p21, in nonsmall cell lung cancer, retinoblastoma protein and, 1329
- Rectal cancer. *See also* Anal cancer; Colorectal cancer
 - distal, sphincter preserving surgery for, 671
- Rectal carcinoids, 1294
- Rehabilitation, postchemotherapy, aerobic exercise in, 1717
- Renal cell carcinoma. *See also* Kidney
 - multifocal, cytogenetics, histopathology and immunology of, 9758
 - prognostic factors in, 2171
 - thyroid metastases in, 574
- Renal pelvis, transitional cell carcinoma of, p53 and, 2178
- Research reports, ethical standards for, 626 (letter)
- Retinoblastoma, brain metastases in, 403
- Retinoblastoma protein, in nonsmall cell lung cancer, prognosis and, 1329
- Retinoic acid, for cervical cancer, 1574
- Retroperitoneal germ cell tumors, chemotherapy for, survival after, 161
- Retropharyngeal lymphadenopathy, in nasopharyngeal cancer, computed tomography of, 869
- Reverse transcriptase-polymerase chain reaction assay, for early prostate cancer, 2402
- Rhabdomyosarcoma, chemotherapy for, hepatic venoocclusive disease after, 2435
- Rhoads, Jonathan Evans, *Festschrift* for, 1737
- Richter's syndrome, hypercalcemia in, 1211

S

- Safflower oil, colorectal carcinogenesis and, 1487
- Salivary gland tumors
 - in atomic bomb survivors, 1465
 - p53 and chromosome 17 aberrations in, 2314
- Sarcoma. *See also* Cancer and specific sites and types
 - choroid, of bone, 1903
 - Ewing's, brain metastases in, 403
 - follicular dendritic cell, malignant potential of, 294
 - osteogenic
 - brain metastases in, 403
 - chemotherapy for, timing of, 1343
 - with lung metastases, chemotherapy for, 245
 - MDM2 in, 1541
 - melanoma in, 843
 - neoadjuvant chemotherapy for, 411
 - overexpression of resistance-related proteins in, prognosis and, 2336
 - p53 in, 1541
 - small cell, 2095
- soft tissue
 - in children, brain metastases in, 403
 - melanoma in, 843
 - S-phase fraction in, prognosis and, 2371
 - tumor necrosis factor- α and melphalan isolated limb perfusion for, 1129
- synovial, in children, brain metastases in, 403
- thyroid, 579
- SC-1, on gastric cancer, 433
- Scatter factor, in breast tissue, 749
- Scleroderma, radiation toxicity in, 612
- Screening
 - for breast cancer
 - mortality rates and, 1 (editorial), 69
 - risk-benefit analysis for, 628 (letter)
 - in younger women, survival and, 1923
 - for neuroblastoma, new cell line from, 2036
 - for prostate cancer, age- and race-related incidence and, 99
 - randomized, limitations of, 1740
- Secretory meningioma, 2003
- SEER program, breast, colorectal, lung and prostate cancers in, vs. in National Cancer Data Base, 2052
- Seizures, chlorambucil and, 1009
- Seminomas. *See* Germ cell tumors
- Serotonin, small intestinal carcinoids and, 1086
- Serum alanine aminotransferase, recurrent hepatocellular carcinoma and, 688
- Serum immunoglobulin G1, in colorectal cancer, 1482
- Sex, astrocytoma prognosis and, 370
- Sexual function, prostate cancer treatment and, 538, 1977
- S-HAM, for acute leukemia, 59
- Short chain fatty acids, in gut protection, in chemotherapy, 1794
- Sialyl Lewis^a, in melanoma, 1686
- Sialyl Lewis^x
 - in lung cancer, α -1,3-fucosyltransferase and α -2,3-sialyltransferase and, 1678
 - in melanoma, 1686
- α -2,3-Sialyltransferase, sialyl Lewis^x synthesis and, in lung cancer, 1678
- Silicone breast implants, health implications of, 1747
- Sinuses, paranasal, cancer of, HPV and p53 in, 1321
- Skin cancer, squamous cell
 - desmoplastic, 915
 - metastatic, from actinic keratoses, 920
- Skin ulceration, paclitaxel and, 2266 (letter)
- Small cell carcinoma
 - extrapulmonary, 1729
 - pulmonary, ectopic atrial natriuretic peptide in, 35
- Small cell neuroendocrine carcinoma, of bladder, 356
- Small cell osteosarcoma, clinicopathology of, 2095

- Small intestinal cancer, *ras* mutations in, 1804
 Small intestinal carcinoid tumors, 1086, 1804
 Smoking
 cessation of in relatives of cancer patients, 152
 gastric cancer and, 1840 (letter)
 lung cancer and, in African Americans, 45
 renal cancer and, 2171
 Socioeconomic status
 age peak in acute lymphoblastic leukemia and, 2045
 breast-conserving surgery and, 314
 Soft tissue sarcoma
 in children, brain metastases in, 403
 melanoma in, 843
 S-phase fraction in, prognosis and, 2371
 tumor necrosis factor- α and melphalan isolated limb perfusion for, 1129
 Soft tissue tumors, myxoid, fluorescence in situ hybridization analysis of, 284
 Soluble interleukin-2 receptor, in head and neck cancer, prognosis and, 1401
 Spermatogenesis, doxorubicin-induced damage of, leuporelin protection against, 1014
 S-phase fraction
 in endometrial cancer, prognosis and, 944
 in soft tissue sarcoma, prognosis and, 2371
 Spinal cord tumors, pathologic diagnosis of, consultation for, 796
 Spindle cell tumors, of thyroid, 579
 Squamous cell carcinoma. *See also specific sites*
 esophageal
 basaloid, 1871
 diffuse pagetoid in situ, 1865
 of head and neck. *See* Head and neck cancer
 laryngeal, *bcl-1/cyclin D1* gene in, 1114
 oral, nucleolar organizer regions in, 2200
 of skin
 desmoplastic, 915
 metastatic, from actinic keratoses, 920
 of vermilion surface, desmoplastic, 915
 SR48692 (nonpeptide neurotensin receptor antagonist), for neurotensin-induced pancreatic cancer, 1787
 Staging
 artificial neural networks in, 857
 laparoscopic
 of pancreatic cancer, 1315, 1780
 of upper gastrointestinal tumors, 1315, 1780
 of prostate cancer, 2154
 of thyroid cancer, 2414
 TNM
 vs. artificial neural networks, 857
 for thyroid cancer, 2414
 Stein-Leventhal syndrome, breast cancer and, 494
 Stem cell transplant
 for breast cancer, with chemotherapy, nausea and vomiting after, 1699
 endocrine function and bone metabolism after, 1617
 rehabilitation after, aerobic exercise in, 1717
 Stereotactic radiosurgery, for brain metastases, 551
 Steroids, with flutamide withdrawal, for prostate cancer, 1964
 Stress, breast cancer and, 1055 (letter)
 Surgery. *See also specific sites and types*
 breast-conserving
 for early stage I-II synchronous bilateral cancer, 1362
 margins in, 1453, 1459 (editorial), 1568
 race and socioeconomic status and, 314
 recurrence after, calcifications and, 1355
 for central neurocytoma, 790
 for hilar choriocarcinoma, 26
 Klatskin's tumor, 26
 for rectal cancer, with sphincter preservation, 671
 for recurrent medulloblastoma, 1241
 Surveillance, Epidemiology and End Results (SEER) program, breast, colorectal, lung and prostate cancers in, vs. in National Cancer Data Base, 2052
 Sweden, cutaneous melanoma in, prognostic factors in, 275
 Switzerland, lung cancer histologic trends in, 906
 Synovial sarcoma, in children, brain metastases in, 403
 Systemic lupus erythematosus, radiation toxicity in, 612
 Systemic sclerosis, radiation toxicity in, 612
 T
 Talc, perineal exposure to, ovarian cancer and, 2396
 Tamoxifen
 for breast cancer, increasing incidence and declining mortality with, 69
 for metastatic melanoma, with cisplatin, 1037
 venous thrombosis and, Factor V Leiden and, 2024
 T-cell lymphoma, cutaneous, anti-*HTLV-1* antibody positive, 269
 Tegafur, for colorectal cancer, 1884
 Telomerase, in bladder cancer diagnosis, 362
 Terminal cancer
 cognitive impairment in, 835
 psychiatric morbidity in, 1848 (letter)
 Testicular cancer
 chemotherapy for
 with bone marrow transplant, 1605
 residual pulmonary masses after, 345
 survival after, 161
 with concurrent mediastinal germ cell tumor, 1031
 low stage, prognostic factors in, 1641, 1646 (editorials), 1710
 MIB-1 in, metastasis risk and, 1641, 1645, 1710
 p53, *c-kit* and CD34 in pre- and postpubertal males, 2430
 pulmonary metastasis from, postchemotherapy residua of, 345
 Testicular recurrence, of acute lymphoblastic leukemia, treatment of, 2257
 Thermogenesis, glucose-induced, tumor necrosis factor- α and, in elderly, 177
 Thermography, in breast cancer, 187 (letter)
 Thrombosis
 portal vein

- after chemotherapy for rhabdomyosarcoma, 2435
 - in hepatocellular carcinoma
 - chemotherapy and, 1890
 - transcatheter arterial chemoembolization for, 2087
 - tamoxifen-related, Factor V Leiden and, 2024
 - Thyroid
 - metastases to, 574
 - primary smooth muscle tumors of, 579
 - Thyroid cancer
 - hyperparathyroidism and, 1611
 - insular, in adolescents, 1044
 - medullary, prognosis in, 132
 - micronutrients and, 2186
 - optimal dose of I¹³¹ for, 190 (letter)
 - prognostic factors for, 564
 - staging of, 2414
 - Thyroid function, after bone marrow/blood-derived progenitor cell transplant, 1617
 - Tissue type plasminogen activator, in dedifferentiated chondrosarcoma, 53
 - TNM staging system
 - vs. artificial neural networks, 857
 - for thyroid cancer, 2414
 - Tobacco use
 - cessation of in relatives of cancer patients, 152
 - gastric cancer and, 1840 (letter)
 - lung cancer and, in African Americans, 45
 - renal cancer and, 2171
 - Tonsillar carcinoma, human papillomavirus and, 595
 - Total body irradiation, late effects of, 1617
 - Total parenteral nutrition, for cachexia, 1828
 - Transcatheter arterial chemoembolization, in hepatocellular carcinoma with portal vein obstruction, 2087
 - Transitional cell carcinoma
 - of bladder. *See* Bladder cancer
 - endometrial, 1933
 - of renal pelvis and ureter, p53 and, 2178
 - Transplantation
 - bone marrow
 - endocrine function and bone metabolism after, 1617
 - for epipodophyllotoxin-induced acute myeloid leukemia, 1049
 - for testicular germ cell tumors, with chemotherapy, 1605
 - stem cell
 - for breast cancer, with chemotherapy, nausea and vomiting after, 1699
 - endocrine function and bone metabolism after, 1617
 - rehabilitation after, aerobic exercise in, 1717
 - Trisomy 8, myelodysplastic syndrome with Behcet's syndrome and, 262
 - Tumor angiogenesis
 - in esophageal cancer, vascular endothelial growth factor and, 206
 - in prostate cancer, prognosis and, 772
 - Tumor markers. *See* specific markers
 - Tumor necrosis factor- α
 - glucose metabolism and, in elderly, 177
 - in head and neck cancer, prognosis and, 1401
 - for HPV-associated cancers, 924
 - hypercalcemia in Richter's syndrome and, 1211
 - with melphalan, via isolated limb perfusion, for soft tissue sarcoma, 1129
 - Tumor thrombosis
 - portal vein, in hepatocellular carcinoma, chemotherapy and, 1890
 - of portal vein, in hepatocellular carcinoma, transcatheter arterial chemoembolization for, 2087
 - Type III procollagen, N-terminal peptide of, colorectal cancer recurrence and, 1299
 - Tyrosine autoantibodies, in melanoma and vitiligo, 1461
- ## U
- Ulceration, paclitaxel and, 2266 (letter)
 - Ultrasonography, in pancreatic cancer, 1780
 - Upper gastrointestinal tumors, laparoscopic staging of, 1315
 - Uracil, for colorectal cancer, 1884
 - Ureter, transitional cell carcinoma of, p53 and, 2178
 - Urinary bladder. *See* Bladder
 - Urokinase-type plasminogen activator
 - in dedifferentiated chondrosarcoma, 53
 - in gastric cancer, prognosis and, 878
 - Urothelial cancer, advanced, chemotherapy for, 110
 - Uterine cervix. *See* under Cervical
 - Uveal melanoma, nucleolar size in, prognosis and, 982
- ## V
- Vaginal cancer, clear cell, age peaks in, 2229
 - Valvular surgery, for carcinoid heart disease, tumor regression after, 605
 - Vascular endothelial growth factor, in esophageal cancer, 206
 - Venocclusive disease, hepatic
 - after chemotherapy for rhabdomyosarcoma, 2435
 - in hepatocellular carcinoma, chemotherapy and, 1890
 - Venous thrombosis, tamoxifen-related, Factor V Leiden and, 2024
 - Vermillion surface, desmoplastic squamous cell carcinoma of, 915
 - Vinblastine
 - for advanced urothelial cancer, 110
 - for uterine cancer, 2391
 - Vincristine
 - for acute myelogenous leukemia, long-term follow-up for, 1351
 - with cyclophosphamide, doxorubicin and prednisone, for chronic lymphocytic leukemia, vs. chlorambucil, 2187
 - for multiple myeloma, 1561
 - for rhabdomyosarcoma, hepatic venocclusive disease and, 2435
 - Vinorelbine, for head and neck cancer, 1394
 - Vinyl chloride, hepatocellular carcinoma and, 1671

Vitamin C, thyroid cancer and, 2186
 Vitamin E, thyroid cancer and, 2186
 Vitiligo, melanoma and, tyrosine autoantibodies in, 1461
 Vomiting
 after chemotherapy and stem cell transplant, in breast
 cancer, 1699
 dolasetron for, 1216

W

Waldeyer's ring, squamous cell carcinoma of, HPV and, 595
 Wilms' tumor
 brain metastases in, 403
 pulmonary metastases in, cytodifferentiation of, 1629
 World Conference for Cancer Organisations, 619

Authors' Index—Volume 79

A

Abbondanzo, S. L., 1656
 Abo, S., 214
 Abramovici, H., 924
 Abramson, A. F., 1355
 Abramson, N., 1561
 Abu-Abid, S., 1129
 Adair, C. F., 579
 Agostara, B., 1394
 Ahsan, H., 1600
 Aiba, M., 558
 Aisenberg, A. C., 1203
 Akaike, M., 688
 Akaza, H., 1014
 Åkervall, J. A., 380
 Akrivos, T., 2391
 Albers, P., 1646, 1710
 Albores-Saavedra, J., 398, 1476, 1933
 Albright, R. E., Jr., 551
 Ali, S. Z., 356
 Allal, A. S., 2329
 Alliegro, M. B., 1004
 Alotto, M., 2354
 Al-Saleem, T. I., 75
 Altermatt, H. J., 989
 Amadori, D., 226
 Amaya, H., 220
 Ambros, R. A., 2162
 Amin, M. B., 1031
 Amiri, A. A., 1686
 Ämmälä, M., 1166
 Anbari, K. K., 1816
 Anderson, K. E., 494
 Anderson, P. M., 1409
 Ando, E., 1890
 Ando, Y., 255
 André, T., 1100
 Ang, K. K., 1279
 Angervall, L., 2125
 Anthony, D. C., 127
 Antman, K. H., 2237
 Aoki, D., 169
 Aoki, T., 284
 Aoyagi, K., 3, 1077
 Apolinario, R., 2178
 Araki, N., 411
 Arase, Y., 1494
 Ardizzoni, A., 1897
 Arimoto, J., 1533

Armin, D., 551
 Arvas, M., 944
 Arya, G., 1757
 Ashfaq, R., 1933
 Aspegren, K., 69
 Astone, A., 1501
 Athanasiadis, I., 588
 Atkins, J. N., 152
 Au, G. K. H., 869
 Auranen, A., 2147
 Avanzini, P., 1234
 Ayala, A. G., 53
 Aydinli, K., 944

B

Babul, N., 1428
 Bacci, G., 245
 Bade, S., 1723
 Bahadur, Y. A., 81, 328
 Baharav, E., 1461
 Bajetta, E., 1394
 Bakker, A. J., 935
 Bakker, P. J. M., 935
 Balch, C. M., 1122
 Baldini, L., 1234
 Baldin, G., 69
 Balm, A., 380
 Balter-Seri, J., 1241
 Bannwart, F., 1031
 Baranda, J., 1767
 Barker, F. G., II, 115
 Barón, M. G., 1884
 Barquin, N., 2430
 Barron, B. A., 1951
 Barth, A., 1862, 1918
 Basso, D., 1299
 Bauer, J. J., 952
 Bauer, P. M., 1686
 Beaudreuil, J., 1211
 Becich, M. J., 2424
 Becker, R. L., 982
 Beerblock, K., 1100
 Beguin, Y., 1351
 Behrendt, H., 2257
 Benchalal, M., 2137
 Benedict, C. R., 1216
 Benedict, W. F., 1329
 Ben-Izhak, O., 18
 Benson, M. C., 2402
 Berg, J., 1343
 Berg, K., 2282
 Berger, D., 700
 Berger, F., 1671
 Bergholm, U., 132
 Bergmann, M., 2003
 Bergström, R., 132
 Berking, C., 843
 Berkowitz, I. M., 152
 Berner, A., 1172
 Bernhard, J., 1703
 Bernheim, J., 2229
 Bertoni, F., 245
 Bertrand, G., 2371
 Bertz, H., 1717
 Beşe, T., 944
 Bessho, T., 1533
 Bettencourt, M.-C., 952
 Beyer, J., 161
 Bierhoff, E., 1646, 1710
 Biesma, D. H., 1548
 Birch, R., 740
 Bittinger, F., 1871
 Black, P. M., 127
 Blackbourne, L. H., 1776
 Blandamura, S., 425
 Blok, P., 390
 Blough, R., 588
 Bociek, R. G., 328
 Bodey, G., 1150
 Bodner, S. M., 2243
 Boivin, J.-F., 1203
 Boletini, A., 1114
 Bollen, A., 2028
 Bolodeoku, J., 362
 Bonavida, B., 1180
 Bonavina, L., 425
 Bond, J. R., 2095
 Bonichon, F., 2371
 Bonin, S. R., 75
 Bonsing, B. A., 1304
 Borg, Å., 380
 Borgen, P., 1355
 Bornstein, J., 924
 Bosari, S., 425, 761
 Bossi, P., 425
 Bostwick, D. G., 337, 857, 2154
 Bouffet, E., 403
 Bourgeois, F. J., 1776
 Bowman, W. P., 1049
 Boyd, J. H., 1623, 2016

- Boyle, P., 2209
 Boysen, M., 2200
 Bozik, M. E., 849
 Brady, M. S., 843
 Brand, C. U., 2345
 Breneman, J. C., 551
 Breuninger, H., 915
 Briccoli, A., 245
 Brierley, J. D., 1422, 2414
 Brouillet, J.-P., 2132
 Broun, E. R., 1605
 Brown, R., 920
 Brown, R. D., 2073
 Bruderman, I., 468
 Bruera, E., 835
 Brugiattelli, M., 2107
 Brun, B., 2137
 Brunat-Mentigny, M., 403
 Bruner, J. M., 796
 Brunin, F., 1401
 Bu, S.-Z., 1944
 Buchanan, G. R., 1049
 Büchner, T., 59
 Bucky, L. P., 1816
 Budd, G. T., 500
 Buffa, R., 425, 1114
 Bulten, J., 2229
 Burger, M. M., 416
 Burger, P. C., 790
 Burk, M., 2193
 Burke, A. P., 1086
 Burke, H. B., 857
 Burmeister, L. A., 1611
 Burnham, J. A., 1587
 Bury, J., 1351
 Busse, P. M., 671
 Bussman, J. W., 656
 Buttyan, R., 2402
 Buzdar, A. U., 730
- C**
- Cady, B., 1856, 2482
 Cady, J., 1094
 Cain, A., 2440
 Calvieri, S., 2354
 Campbell, J. W., 849
 Capaccio, P., 1114
 Carboni, N., 1114
 Carola, E., 1094, 1100
 Carrie, C., 403
 Carty, S. E., 1611
 Caruana, S. M., 1320
 Casagrande, Y., 1767
 Casassus, P., 1211
 Castiglione, M., 1703
 Catalano, C. J., 1776
 Caturelli, E., 1501
 Cavanna, L., 1234
 Cawkwell, L., 684
 Cedrone, A., 1501
 Cha, S. S., 337
 Chaitchik, S., 1129
 Chan, J. K. C., 294
 Chang, H., 700
 Chang, S., 2396
 Chang, S. M., 115
 Chap, L., 1698
 Chassevent, A., 2371
 Chayama, K., 1494
 Chen, H.-C., 35
 Chen, P.-L., 494
 Chen, Y.-T., 2209
 Cheng, X., 521
 Chi, J. G., 1995
 Chinn, D. O., 963
 Chinn, J., 963
 Chinn, M., 963
 Chiusa, L., 1956
 Cho, B.-K., 1995
 Cho, J. Y., 462, 878
 Choi, I. J., 2087
 Choi, J.-H., 1879
 Choi, K. S., 1995
 Chou, M.-C., 2209
 Chou, P. M., 2430
 Choy, D. T. K., 869
 Christen, R. D., 1037
 Christopherson, W. A., 1587
 Chu, P., 1865
 Chua, D. T. T., 869
 Chung, H. C., 462, 878
 Chung, J. W., 2087
 Chung, K. Y., 462
 Chung, Y.-S., 695
 Cirrincione, C., 2237
 Citron, M. L., 2237
 Clamon, G. H., 152
 Clausen, O. P. F., 2200
 Claussen, U., 975
 Clayman, G. L., 1279
 Coca, S., 2320
 Cocker, R., 1320
 Cockerell, C., 920
 Coggi, G., 425
 Cohen, H., 18
 Cohen, I. J., 1241
 Cohen, M. A. H., 500
 Cohen, M. H., 724
 Cohen, R., 468
 Cohn, J. B., 724
 Cohn, K. H., 233
 Coindre, J.-M., 2371
 Coit, D. G., 1635
 Collin, F., 2371
 Colmenarejo, A., 1884, 2320
 Colombi, M., 1234
 Conaway, M. R., 152
 Connelly, R. R., 952
 Connolly, C., 2219
 Connolly, J. L., 1362, 1459, 1568
 Cook, N., 595
 Coons, S. W., 1381
 Cooper, D. L., 1009
 Cooper, K., 294
 Copeland, E. M., III, 1828
 Corn, B. W., 2409
 Cornelisse, C. J., 1304
 Cornetta, K., 1605
 Corsini, A., 1299
 Corson, J. M., 2237
 Cosimi, A. B., 2361
 Coughlin, S. S., 2171
 Cowan, K. H., 1595
 Craig, P. H., 1918
 Crook, J. M., 81, 328
 Crookes, P., 1767
 Crosson, F. J., 661
 Csóka, K., 1225
 Cuatrecasas, M., 1581
 Curley, S. A., 1294
 Curran, W. J., Jr., 2409
 Curreli, L., 1394
 Czerniak, B., 53
- D**
- D'Agostino, R. B., Jr., 145
 Daly, J. M., 1737
 Dämmrich, J., 433
 Damodaran, A., 35
 Daures, J.-P., 1195
 D'Avanzo, B., 2186
 Dave, B. J., 1527
 Davis, D. H., 804
 Dawson, M., 2385
 De Benedetti, A., 2385
 de Castro, J., 1884
 de Gramont, A., 1094, 1100
 DeHaven, J. L., 1987
 Deka, A., 2424
 de la Gándara, I., 1884
 Delattre, J.-Y., 1195
 DeLellis, R. A., 761
 Delmore, J. E., 1951
 de Luca, F., 1501
 Demers, R. Y., 441
 Demirkiran, F., 944
 Deneux, L., 1401
 Denis, L., 1248
 De Paoli, M., 1299
 Dershaw, D. D., 1355
 Desogus, A., 1394
 de Vries, G. M., 2402
 de Wit, L. T., 1315
 Dhar, S., 1225
 Diakomanolis, E., 2391
 Dictor, M. R., 380

DiFino, S. M., 152
 Di Gregorio, C., 1394
 Dimeo, F. C., 1717
 Dimopoulos, M. A., 2391
 Dinehart, S. M., 920
 Di Primio, O., 1956
 Dixon, M. F., 684
 Donaldson, S. S., 2435
 Donati, D., 245
 Donohue, J. P., 345
 Doppke, K. P., 1203
 Dorrucchi, M., 1004
 Dosaka-Akita, H., 1329
 Doumi, N., 403
 Dreicer, R., 110
 Duan, R.-D., 448
 Dubray, B., 1401
 Dudrick, S. J., 1737
 Dufour, F., 2132
 Dufour, M. S., 538
 Dunleavy, T. L., 1623, 2016
 Dunn, J. L., 233
 Dunphy, C. H., 1623, 2016
 Dunphy, F. R., 1623, 2016
 Duray, P., 1964
 Duray, P. H., 1595
 Durham, C., 2219
 Dutcher, J. P., 1022
 Dutkowski, P., 1871

E

Earle, J., 2193
 Eberle, R. C., 1320
 Edelsberg, C., 233
 Edwards, R. P., 1587
 Egawa, S., 90, 1969
 Eidelman, S., 18
 Einhorn, L. H., 110, 1605
 Einstein, D. M., 500
 Einzig, A., 1022
 Ekbohm, A., 132
 Ellis, L. M., 1294
 Ellwanger, U., 2345
 Elsayed, A. M., 1086
 Endo, I., 892
 Engeler, D. S., 1031
 Ennis, R. D., 1600, 2402
 Epstein, J. I., 772
 Erkün, E., 944
 Esche, B. A., 81, 328
 Esparza-Guerra, L., 1150
 Espinosa, E., 1884
 Espinosa, J., 1884
 Essner, R., 1686
 Estelberger, W., 1482
 Evers, B. M., 1787
 Eyre, H. J., 658

F

Facher, E. A., 2424
 Faist, M., 370
 Falkson, G., 1138
 Farris, A., 1394
 Favre, R., 1100
 Federico, M., 1234
 Feig, B. W., 1294
 Feliu, J., 1884
 Fellows, G., 362
 Felts, P. M., 644
 Fernández, Y., 1884
 Ferrari, S., 245
 Ferree, C. R., 145
 Ferrero, S., 425
 Feuillard, J., 1211
 Fields, A., 1574
 Figg, W. D., 1964
 Fillet, G., 1351
 Fimmers, R., 1646, 1710
 Fink, D. J., 640
 Finkelstein, D. M., 1203
 Finkelstein, S. D., 1587
 Fioretti, M., 1897
 Fisher, E. R., 1453
 Fisher, H. A. G., 2162
 Fishman, P., 1461
 Fletcher, B. D., 2243
 Fletcher, C. D. M., 294, 1903
 Fleuren, G. J., 1304
 Fleury, A., 1195
 Folsom, A. R., 494
 Foote, R. L., 2193
 Forget, P., 1351
 Formiconi, A., 1956
 Forni, C., 245
 Fossá, S. D., 345
 Fowble, B., 1061
 Fracchiolla, N. S., 1114
 Franceschi, S., 906, 2186
 Frank, A. R., 2193
 Franks, L. M., 2028
 Frappaz, D., 403
 Frascini, G., 1150
 Fredrix, E. W. H. M., 717
 Freedman, T. G., 2063
 Fridborg, H., 1225
 Fridman, W. H., 1401
 Friedman, D. J., 1049
 Friend, S., 416
 Frola, C., 1897
 Frytak, S., 1729
 Fuchs, A., 749
 Fujii, A., 90, 1969
 Fujimoto, S., 884
 Fujino, M., 1329
 Fujisawa, T., 474
 Fujishima, M., 3, 1077

Fujiwara, H., 505
 Fukatsu, H., 255
 Fukayama, N., 900
 Fukumoto, M., 1180
 Fukushima, S., 780
 Fuller, G. N., 796
 Fulton, N., 1804
 Fung, T. S., 538
 Furukawa, M., 139

G

Gabbert, H. E., 1871
 Gabel, M., 2380
 Galanis, E., 1729
 Galeotti, F., 1299
 Gallagher, R., 1574
 Galliano, D., 1956
 Gambardella, A., 177
 Ganzenko, N., 588
 Gao, Q.-R., 1944
 Garbe, C., 2345
 Garcia, M., 2132
 Garden, A. S., 1279
 Garfinkel, L., 1853
 Garne, J. P., 69
 Gasbarrini, G., 1501
 Gaudio, M., 226
 Geara, F. B., 1279
 Gebbia, N., 1394
 Gebbia, V., 1394
 Gebhardt, M. C., 1343
 Geiger, B., 468
 Geisinger, K. R., 1158
 Gelman, R. S., 1362
 Gerber, H. A., 989
 Gerl, A., 345
 Gershenson, D. M., 1951
 Geyer, R. J., 1438
 Gharib, H., 574
 Ghosh, K., 320
 Giacco, G. G., 1294
 Giannakoulis, N., 2391
 Giercksky, K.-E., 2282
 Giess, C. S., 1355
 Gilchrist, G. S., 2251
 Gilchrist, K. W., 1138
 Gilliland, F. D., 564
 Giorgi, G., 1897
 Girón, C. G., 1884
 Gitelis, S., 1903
 Gize, G., 1605
 Glick, J. H., 1561
 Glisson, B. S., 1279
 Gloor, B., 1780
 Gobbi, P., 1234
 Goellner, J. R., 574, 1044
 Goepfert, H., 1279
 Gohji, K., 90, 1969
 Goldberg, G., 1574

Goldberg, I. D., 749
 Goldfarb, P. M., 640, 0646
 Gollamudi, S. V., 1362
 Gomyo, Y., 2067
 Gondo, T., 1647
 Gong, S. J., 462
 González, D. G., 935
 Gonzalez-Crussi, F., 2430
 Goodison, S., 362
 Goodman, P. H., 857
 Goodrow, T., 700
 Gospodarowicz, M. K., 1422, 2414
 Gouma, D. J., 1315
 Graham, S. D., Jr., 545
 Gralla, R. J., 1216
 Grattagliano, A., 1501
 Graziani, D., 425
 Greco, F. A., 740
 Green, M. R., 2237
 Grenier, J., 2132
 Grénman, S., 2147
 Greven, K. M., 145
 Groeger, J. S., 1635
 Groisman, G., 18
 Grosclaude, P., 1195
 Groshen, S., 1767
 Gross, A., 35
 Gross, T. G., 1629
 Grote, T. H., 1216
 Guber, A., 468
 Guerry, D., IV, 1816
 Guffanti, A., 1234
 Guidi, A. J., 1459, 1568
 Guillevin, L., 1211
 Guinan, P., 2430
 Gulavita, S., 2193
 Gullotta, F., 2003
 Gully, D., 1787
 Gunderson, L. L., 2251
 Gusset, H., 1703
 Guthrie, B. L., 804
 Gutman, M., 1129

H

Haas, R., 1617
 Habbema, J. D. F., 345
 Häckel, C., 53
 Haddock, M. G., 337, 0790
 Hagen, N. A., 1428
 Hagiwara, S., 558
 Hahne, W. F., 1216
 Hailemariam, S., 1031
 Hainsworth, J. D., 740, 1216
 Hakim, R., 127
 Hall, P. D., 1037
 Hallam, S., 1574
 Halpern, A. C., 1816
 Hamazaki, M., 2036
 Hamilton, R., 1816

Hamilton, R. L., 849
 Han, D. H., 1995
 Han, W. S., 1879
 Hanks, G. E., 75
 Hanlon, A. L., 75
 Hanselaar, A., 2229
 Hanselmann, S., 1703
 Hanson, J., 835
 Harada, M., 1329
 Harmon, D. C., 2237
 Harper, J. L., 1629
 Harrell, F. E., Jr., 857
 Harrington, D. P., 1561
 Harris, J. R., 1362, 1459, 1568
 Harris, R. B., 35
 Harrison, B. R., 1623, 2016
 Harvei, S., 1172
 Hashimoto, H., 284
 Hashimoto, M., 214
 Hassoun, A. A. K., 1044
 Hasz, D. E., 1409
 Hata, J.-i., 2036
 Hauck, W., 2409
 Hawkins, N. J., 1106
 Hay, I. D., 1044
 Hayashi, H., 1647
 Hayashi, S., 1552
 Hayashi, Y., 1465
 Hayden, J. D., 684
 Hayner-Buchan, A. M., 2162
 Haynes, H., 1574
 Healey, J., 1541
 Heath, C. W., 700
 Heatley, G. J., 761
 Hecht, J. R., 1698
 Heep, H., 1871
 Heering, K. J., 390
 Heffess, C. S., 579
 Heidenreich, A., 1641
 Heitjan, D. F., 2402
 Hellman, S., 2275
 Hellmich, M. R., 1787
 Helmerhorst, T., 2229
 Helmerhorst, T. J. M., 935
 Hemmer, J., 2309
 Henry-Amar, M., 1195
 Hensel, F., 433
 Henson, D. E., 857
 Hering, F., 1703
 Hermans, J., 390, 1304
 Herndon, J. E., II, 2237
 Hertervig, E., 448
 Herts, B. R., 500
 Hesketh, P. J., 1216
 Hiddemann, W., 59
 Higashide, S., 1787
 Higuchi, Y., 1487
 Hill, D., 619

Hilton, J. G., 2016
 Hilton, N. E., 2380
 Hirai, I., 1533
 Hiraiwa, H., 2036
 Hirose, T., 989
 Hirschmann, C., 1482
 Hisaoka, M., 284
 Holford, T. R., 2209
 Holowiecki, J., 2107
 Holschneider, C. H., 320
 Holzsuh, J., 915
 Hong, C.-P., 494
 Hong, W. K., 1279
 Hopkins, L. G., 740
 Horan, M. A., 1338
 Horiuchi, H., 2336
 Horny, H.-P., 915
 Hortobagyi, G., 1150
 Horvath, E., 804
 Horwitz, S. B., 1022
 Hosokawa, K., 900
 Howell, S. B., 1037
 Hromas, R. A., 1605
 Hu, S.-X., 1329
 Huang, L., 700
 Huang, X., 1122
 Hughes, K., 761
 Huhn, D., 161
 Hunt, W. C., 564
 Hurwitz, C. G. H., 1438
 Hussey, D. H., 612
 Huszar, M., 468
 Huvos, A. G., 1541

I

Iacopino, P., 2107
 Ide, M., 558
 Iezzoni, J. C., 1776
 Iida, M., 3
 Iijima, T., 2336
 Iishi, H., 454
 Ikeda, H., 1516
 Ikeda, K., 1494
 Ikeda, M., 2067
 Ikeguchi, M., 2067
 Ikemoto, S., 780
 Imamura, T., 2336
 Inbar, M., 1129
 Ingvar, C., 275
 Inoue, H., 1678
 Inoue, K., 206
 Inouye, L., 796
 Inwards, C. Y., 1903
 Isawa, E., 884
 Ishida, K., 1069
 Ishida, T., 2336
 Ishii, H., 1516
 Ishikawa, A., 513
 Ishikawa, O., 454

Ishizu, H., 1757
 Israel, V. K., 2024
 Itamochi, H., 521
 Ito, H., 2067
 Itoh, H., 12
 Iverson, D., 619
 Ivy, S. P., 2435
 Iwama, H., 1552
 Iwanaga, S.-i., 1077
 Iwasaki, T., 1911
 Iwase, K., 1787
 Iwata, H., 255
 Izumi, T., 892

J

Jacob, P., 1671
 Jaksic, B., 2107
 Jalón, J. L., 1884
 Jaulerry, C., 1401
 Jefferson, M. F., 1338
 Jenkins, J. J., 2440
 Jennings, S., 1574
 Jiang, H., 1527
 Jiang, L.-Z., 1944
 Jimbo, M., 558
 Jin, L., 749
 Jin, P. Y., 724
 Jin, Y., 380
 Johnson, B. E., 35
 Johnson, P. C., 1381
 Johnston, D., 684
 Jolitz, G., 1923
 Jolivet, J., 740
 Jonas, D., 1723
 Jones, J. A., 1037
 Jones, R. S., 1776
 Jones, S. E., 730
 Jonsson, N., 275
 Joseph, A., 749
 Jouvett, A., 403
 Jung, H.-W., 1995
 Jung, K., 104
 Junker, K., 975
 Junker, U., 975

K

Kagami, Y., 1516
 Kahn, M. J., 337, 2154
 Kaibara, N., 12, 2067
 Kakita, A., 688, 1287
 Kaleli, S., 944
 Kallakury, B. V. S., 2162
 Kalman, L. A., 1216
 Kanamori, Y., 521
 Kanbour, A. I., 1587
 Kanbour-Shakir, A., 1587
 Kanz, L., 1717
 Kaplan, E. L., 1804

Kaste, S. C., 2440
 Katagiri, H., 255
 Katsanis, E., 1409
 Katsuki, Y., 169
 Katsuyama, T., 1069
 Kattan, M. W., 528
 Katz, A. E., 2402
 Kaufman, R. P., Jr., 2162
 Kawabe, J., 695
 Kawai, H., 214
 Kawakami, Y., 1329
 Kawakubo, K., 1552
 Kawasaki, H., 1521
 Kawasaki, S., 1069
 Kawashima, M., 1911
 Keilholz, U., 1617
 Keizer, H. J., 345
 Kelley, M. C., 1686
 Kern, W., 59
 Kerner, H., 18
 Keul, J., 1717
 Key, C. R., 564
 Khan, K. K., 1009
 Khanna, C., 1409
 Khojasteh, A., 1216
 Kies, M. S., 588
 Kigawa, J., 521
 Kikuchi, A., 269
 Kikuchi, H., 262, 2036
 Kilpatrick, S. E., 1903
 Kim, B. S., 462, 0878
 Kim, C. Y., 2087
 Kim, D. G., 1995
 Kim, H. J., 1787, 2016
 Kim, I. H., 1995
 Kim, J. H., 462
 Kim, J. S., 2087
 Kim, S. J., 1879
 Kim, S. K., 462
 Kim, Y. B., 320
 Kim, Y. S., 1879
 Kimura, O., 12
 Kinarty, A., 924
 Kingreen, D., 161
 Kinoshita, I., 1329
 Kishimoto, T., 780
 Kitamura, M., 214
 Kitamura, T., 454
 Kitaoka, A., 220
 Kjellberg, J. L., 1977
 Klausner, J. M., 1129
 Klausner, J. S., 1409
 Klein-Szanto, A. J. P., 700
 Klemi, P.-J., 2147
 Klempnauer, J., 26
 Kluin, P. M., 390
 Kluin-Nelemans, H. C., 390
 Knobloch, J., 1723

Knöfel, B., 975
 Knospe, W., 1561
 Kobayashi, K., 884
 Kobayashi, M., 1494
 Kobayashi, N., 1287
 Kodama, T., 1521
 Koerner, F. C., 1203
 Kohno, T., 262
 Koida, I., 1494
 Koide, S., 1678
 Kondo, H., 900
 Kongshaug, M., 2282
 Koops, H. S., 345
 Körbling, M., 1617
 Korff, M. v., 433
 Kösebay, D., 944
 Koshiba, K., 90
 Kosmehl, H., 975
 Kouho, H., 284
 Koulos, J. P., 505
 Koura, A. N., 1294
 Kovacs, K. T., 804
 Kowalski, L. D., 1587
 Kramer, M. H., 390
 Krause, M., 161
 Krc, I., 2107
 Kreth, F. W., 370
 Krol, A. D., 390
 Kroog, G., 1964
 Krulik, M., 1094, 1100
 Kubo, O., 558
 Kubus, J. J., 2073
 Kuipers-Dijkshoorn, N. J., 1304
 Kukiatinant, N., 551
 Kumada, H., 1494
 Kun, L. E., 2440
 Kuroda, N., 1509
 Kurtz, J. M., 2329
 Kusec, R., 2107
 Kute, T. E., 1158
 Kuwao, S., 90
 Kuzumaki, N., 1329
 Kvols, L. K., 605, 830
 Kwong, D. L. W., 869
 Kyle, R. A., 1561

L

Lacroze, M., 403
 Ladanyi, M., 1541
 Lahat, N., 924
 Lahl, R., 2003
 Laine, L., 1767
 Lamm, D. L., 1987
 Lamszus, K., 749
 Land, C. E., 1465
 Lanfranco, C., 1897
 Lange, B. J., 1438
 Langeveld, N. E., 2257
 Langford, L. A., 796

- LaPaix, F. D., 233
 Lara, P. C., 2178
 Larsson, R., 1225
 La Vecchia, C., 906, 2186
 Law, J. C., 2424
 Lazar, L., 441
 Lazarus, P., 1320
 Lazova, R., 2115
 Le, P. T., 35
 Lebas, C., 2137
 Lebourgeois, J.-P., 2137
 Lee, A. K. C., 761
 Lee, C. C. R., 780
 Lee, H.-S., 2087
 Lee, N. Y., 1879
 Lee, W. R., 75
 Lee, Y. H., 462
 Leichman, C. G., 1767
 Leichman, L., 1767
 Lein, M., 104
 Lemamy, G., 2132
 Lembo, T., 1698
 Lemon, S. J., 2066, 2219
 Lenoir, G., 2219
 Lerman, C., 2219
 Lester, E. P., 588
 Levi, F., 906
 Lev-Shlush, D., 1129
 Levy, R., 18
 Lewin, J. C., 653
 Li, B. D. L., 2385
 Li, X., 2314
 Liberman, L., 1355
 Lichtenstein, S. V., 1809
 Liebman, H. A., 2024
 Lin, M., 2137
 Lindberg, G. M., 1476
 Linehan, M., 1595
 Lining, R. A., 1933
 Lippman, S. M., 1279
 Litle, V. R., 1664
 Liu, L., 2385
 Lloyd, R. V., 804, 1729
 Loda, M., 761
 Loeffler, J. S., 127
 Loehrer, P. J., 110
 Loening, S. A., 104
 Loftus, B., 380
 Lonardo, F., 1541
 Lopes, M. B. S., 989
 Loprinzi, C. L., 2193
 Lortholary, O., 1211
 Lortholary, P., 1211
 Losonczi, H., 2107
 Louvet, C., 1094, 1100
 Lu, C., 220
 Lucas, S. B., 1338
 Lucchi, E., 1094
 Lutz, D., 2107
 Lynch, H., 700
 Lynch, H. T., 2066, 2219
 Lynch, J. F., 2066, 2219
 Lyons, M. K., 790

M
 Ma, C. K., 2073
 Mabuchi, K., 1465
 Machinami, R., 2336
 Mackarem, G., 761
 Mackowiak, P., 2073
 Maebeya, S., 1533
 Maeta, M., 12
 Magni, E., 226
 Mahgoub, N., 1438
 Maibach, R., 1703
 Maiolo, A. T., 1234
 Makino, M., 12
 Mal, F., 1094
 Maltoni, M., 226
 Manabe, F., 1014
 Mandeli, J., 1574
 Manfrini, M., 245
 Mani, J.-C., 2132
 Mantovani, G., 1394
 Marcus, S. M., 2409
 Marina, N. M., 2243
 Maris, J. M., 1438
 Marks, J. R., 857
 Marks, L. B., 668
 Marom, Z., 468
 Marti, M.-C., 2329
 Martin, A., 1211
 Martin, I. G., 684
 Martinez, A. J., 849
 Martinez, D., 2320
 Martos, J. A., 2320
 Maruyama, Y., 139
 Måsbäck, A., 275
 Matias-Guiu, X., 1581
 Matsukura, T., 1911
 Matsumoto, H., 269
 Matsumura, M., 220
 Matsuura, H., 1465
 Matsuzaki, I., 214
 Matthay, K. K., 2028
 Maurer, H. M., 2435
 Max, R., 1617
 May, D., 2115
 Mayr, N. A., 612
 McCarthy, W. H., 1122
 McClay, E. F., 1037
 McClay, M.-E. T., 1037
 McCormick, B., 1355
 McCormick, S. A., 1320
 McCurdy, J. B., 982
 McDonough, E. M., 1623, 2016
 McGill, F., 1574
 McGrady, M. D., 1623
 McLean, I. W., 982
 McLeod, D. G., 952
 McPherson, C. P., 1923, 1977
 Mehta, R. R., 1158
 Meier, F., 2345
 Meller, I., 1129
 Mena, H., 398
 Menck, H. R., 2052
 Menegoz, F., 1195
 Mercuri, M., 245
 Merimski, O., 1461
 Merino, M. J., 1595
 Mermillod, B., 2329
 Mertelsmann, R., 1717
 Mertens, F., 380
 Messemer, J. E., 345
 Mettlin, C. J., 2052
 Meyer, J. I., 500
 Meyer, W. H., 2243
 Meyer-Bahlburg, A., 433
 Michalas, S., 2391
 Michalides, R. J. A. M., 380
 Michalski, T. A., 314
 Mick, R., 1816
 Mieno, H., 1287
 Miller, B. E., 1951
 Mimura, Y., 2314
 Min, J. S., 878
 Minagawa, Y., 521
 Minamiya, Y., 214
 Mineta, H., 380
 Minster, J. R., 1623, 2016
 Mion, F., 1671
 Misselevich, I., 18
 Mitchell, M. F., 505
 Mitsuishi, T., 1911
 Mittal, B. B., 588
 Miyoshi, S., 1533
 Mizutani, Y., 1180, 1190
 Moan, J., 2282
 Modiano, M. R., 1216
 Modlin, I. M., 813
 Moertel, C. G., 830
 Moir, C. R., 2251
 Molberg, K. H., 1476
 Moldawer, L. L., 1828
 Monti, C., 245
 Montz, F. J., 320
 Moore, D. II, 1664
 Mor, C., 1241
 Morabito, F., 2107
 Moran, C. A., 398
 Morant, R., 1703
 Moreno, M., 2320
 Morimura, K., 780
 Morisue, K., 1969
 Morita, S., 513

Morris, D. M., 564
 Morris, E., 1355
 Morton, D. L., 1686
 Moschella, F., 1394
 Moskaluk, C. A., 1595
 Moss, S. M., 1
 Mosseri, V., 1401
 Mott, L. A., 233
 Mottolese, C., 403
 Moul, J. W., 952, 1641
 Movsas, B., 75
 Moynes, R., 2115
 Mozes, M., 1129
 Mukai, K., 900
 Müller, S. C., 1646, 1710
 Müller-Hermelink, H. K., 433
 Muraca, P. J., 2162
 Muraoka, R., 220
 Murashima, N., 1494
 Muroso, S., 139
 Murphy, G. P., 1248, 2052
 Murray, C. L., 1923, 1977
 Mustafa, M. M., 1049
 Mutou, T., 884
 Myoui, A., 411

N

Nagabuchi, E., 1757
 Nagahama, H., 1516
 Nagai, K., 1521
 Naito, Y., 1533
 Nakagawara, G., 892
 Nakaizumi, A., 454
 Nakajima, H., 2095
 Nakamura, S., 3, 1077
 Nakano, A., 892
 Nakano, T., 513
 Nakata, B., 695
 Nakata, H., 284
 Nakatani, T., 780
 Nakhjavani, M. K., 574
 Nakhleh, R. E., 2073
 Nanni, O., 226
 Nargund, V., 362
 Narod, S., 2219
 Nasu, M., 262
 Nathanson, S. D., 2380
 Nattinger, A. B., 314
 Naus, G. J., 1587
 Nayler, S. J., 294
 Neaton, J. D., 2171
 Negri, E., 2186
 Nelson-Adesokan, P., 920
 Neri, A., 1114
 Nesland, J. M., 2282
 Neu, D., 1646, 1710
 Neuberg, D., 1067, 1138
 Neugut, A. I., 1600
 Neville, M., 1409

Ng, A. K., 671
 Nichols, C. R., 1605
 Nieberg, R. K., 320
 Nilsson, Å., 448
 Nishida, J., 482
 Nishihara, T., 695
 Nishikawa, T., 269
 Nishimura, M., 1521
 Nishimura, S., 695
 Nishisaka, N., 780
 Nishiwaki, Y., 1521
 Nitecky, S., 18
 Noh, S. H., 878
 Nomi, M., 1969
 Noone, R. B., 1747
 Noordijk, E. M., 390
 Northway, R. O., 545
 Nose, H., 1516
 Novotny, P. J., 2193
 Nozawa, S., 169
 Nyberg, L., 448
 Nygren, P., 1225
 Nyman, T., 1166

O

Obara, T., 700
 Obertop, H., 1315
 O'Boyle, K. P., 1022
 Ochi, H., 695
 O'Connor, T., 1106
 Odén, A., 2125
 Odom-Maryon, T., 595
 Ogawa, J.-I., 1678
 Oh, J. Y., 1879
 Ohata, Y., 269
 Ohbu, M., 1287
 Ohgashi, H., 454
 Ohkawa, S., 688
 Ohkubo, H., 884
 Ohkura, H., 900
 Ohno, E., 262
 Ohori, M., 90, 1969
 Ohtsu, A., 900
 Ohtsuka, E., 262
 Ohyashiki, J. H., 1552
 Ohyashiki, K., 1552
 Oka, K., 513
 Oka, M., 1647
 Okada, M., 521
 Okada, S., 1516
 Okada, Y., 1180, 1190
 Okamoto, E., 1509
 Okamoto, M., 1969
 Okamura, T., 695
 Okayasu, I., 1287
 Oken, M. M., 1561
 Okuno, S. H., 2193
 Okusaka, T., 1516
 Olson, J. E., 1067, 1138

Olsson, H., 275
 Orinon, E., 2219
 Ornstein, D. L., 233
 Ortega, J. A., 2435
 Osaki, M., 2067
 Ostertag, C. B., 370
 O'Sullivan, B., 2414
 O'Toole, K. M., 2402
 Öz, U. A., 944
 Ozeki, Y., 206

P

Paek, S. H., 1995
 Paliard, P., 1671
 Pallavicini, M. G., 1664
 Pandya, K. J., 1138
 Panzarella, T., 2414
 Paolisso, G., 177
 Papadimitriou, C. A., 2391
 Pappo, A., 2435
 Pappo, A. S., 2440
 Parham, D. M., 2243
 Park, C.-S., 139
 Park, J. H., 2087
 Park, M., 749
 Partensky, C., 1671
 Partin, A. W., 772
 Pathak, S., 1527
 Patronas, N., 1964
 Paz, I. B., 595
 Pearl, D. K., 1381
 Pei, G., 1944
 Peiro, G., 1362
 Pekonen, F., 1166
 Pellegata, N. S., 226
 Pelzer, H. J., 588
 Pendleton, N., 1338
 Peng, Q., 2282
 Pennington, E. C., 612
 Pennucci, M. C., 1897
 Peracchia, A., 425
 Perchinsky, M. J., 1809
 Pereira, J., 835
 Perez-Piqueras, J., 2320
 Pernicone, P. J., 804
 Perry, G. A., 81, 0328
 Pestalozzi, D., 1703
 Peters, L. J., 1279
 Petraglia, S., 2354
 Petrek, J. A., 1271
 Pezzotti, P., 1004
 Phipps, K., 233
 Piazza, M., 425
 Pich, A., 1956
 Pichlmayr, R., 26
 Piedbois, P., 2137
 Pieresca, C., 1234
 Pignataro, L., 1114
 Pintillie, M., 1422

Pisansky, T. M., 337, 2154
 Pitot, H. C., 605
 Planinc-Peraica, A., 2107
 Plebani, M., 1299
 Plourde, P., 730
 Point, D., 1401
 Poisson, M., 1195
 Polednak, A. P., 99
 Pollack, A., 1370
 Pollack, I. F., 849
 Pollock, B. H., 2045
 Pompili, M., 1501
 Postma, A. J., 935
 Pounds, T. R., 115
 Prados, M. D., 115
 Prat, J., 1581
 Pratt, C. B., 2440
 Price, F. V., 1587
 Probst-Cousin, S., 2003
 Pronzato, P., 1897
 Probert, K. J., 110
 Prosnitz, L. R., 668
 Pruneri, G., 1114

Q

Quirke, P., 684
 Quish, A., 1574

R

Rabl, H., 1482
 Rademaker, A., 588
 Radig, K., 53
 Rahman, Z., 1150
 Rameau, R., 1574
 Rand, W. M., 1343
 Randall, B., 2171
 Randimbison, L., 906
 Ranstam, J., 69
 Ranzani, G. N., 226
 Rao, B. N., 2440
 Rapaccini, G. L., 1501
 Raphael, M., 1211
 Rasp, G. M., 337
 Rassner, G., 2345
 Rathmell, A. J., 1422
 Rauws, E. A. J., 1315
 Raverdy, N., 1195
 Ravindranath, M. H., 1686
 Raymond, E., 1094, 1100
 Rayson, D., 605
 Reardon, D. H., 724
 Reber, H. A., 1780
 Recht, A., 671, 1362
 Redondo, E., 2178
 Reed, E., 1964
 Regl, D. L., 1022
 Rembeck, B., 2125
 Ren, X.-H., 1944

Renault, B., 226
 Reuter, V. E., 356
 Revel, M., 924
 Rey, A., 2178
 Rezza, G., 1004
 Ribbert, H., 433
 Rich, S. S., 494
 Richter, M. P., 1138
 Ridder, G. J., 26
 Rietbroek, R. C., 935
 Rifkin, M. D., 2162
 Riggs, C. E., Jr., 612
 Riggs, D. R., 1987
 Rinaldi, Y., 1100
 Risch, H. A., 2396
 Robertson, S. J., 81, 0328
 Robinson, E., 1600
 Robinson, J. W., 538
 Robison, L. L., 2045
 Robsahm, T. E., 1172
 Rochefort, H., 2132
 Rodriguez, J., 1401
 Rodriguez, J. J., 1623, 2016
 Rodriguez-Galindo, C., 2243, 2440
 Roessner, A., 53
 Roh, J. K., 462, 0878
 Ron, E., 2186
 Roncalli, M., 425
 Rorke, L. B., 665
 Rosen, D. B., 857
 Rosen, E. M., 749
 Ross, J. A., 2045
 Ross, J. S., 2162
 Rossner, R., 370
 Rosso, R., 1897
 Roth, A. D., 2329
 Roth, B. J., 110
 Roveroni, G., 1299
 Rubenstein, E. B., 1216
 Rubin, M., 2402
 Ruggeri, B. A., 700
 Runowicz, C. D., 1574
 Rusciani, L., 2354
 Rushin, J., 35
 Russell, R. L., 1158
 Russell, S., 920
 Rutanen, E.-M., 1166
 Ryu, S. K., 1879

S

Saag, K. G., 612
 Saburi, Y., 262
 Saegusa, M., 1287
 Saez, M. A., 2320
 Saitoh, S., 1494
 Saku, T., 1465
 Sakurai, Y., 695
 Salloum, E., 1009
 Samuelsson, M., 2125

Sandberg, M., 1611
 Sanders, W. H., 545
 Sandler, E. S., 1049
 Sandor, A., 813
 Sanguineti, G., 1279
 Santiago, F., 1106
 Sanz, C. R., 2430
 Sarbia, M., 1871
 Sarris, K., 2391
 Sartor, O., 1964
 Sasaki, K., 2314
 Sata, T., 1911
 Sato, H., 139
 Sato, K., 255
 Saurin, J.-C., 1671
 Sautois, B., 1351
 Sawada, T., 695
 Scardino, P. T., 528
 Scarpi, E., 226
 Schacht, B., 1605
 Schaffer, P., 1195
 Schauenstein, E., 1482
 Schauenstein, K., 1482
 Schaumburg-Lever, G., 915
 Scheibenbogen, C., 1617
 Scheithauer, B. W., 790, 804, 989, 1381
 Schiff, D., 790
 Schiff, P. B., 2402
 Schild, S. E., 790
 Schilling, A., 152
 Schilthuis, M. S., 935
 Schlagenhauff, B., 2345
 Schleicher, J., 161
 Schleyer, E., 59
 Schlichter, A., 975
 Schlup, N., 2132
 Schmid, H.-P., 1703
 Schmid, K. W., 2003
 Schneider, L. J., 1362
 Schnitt, S. J., 749, 1362, 1459, 1568
 Schnorr, D., 104
 Schoene, W. C., 804
 Schomberg, P. J., 2251
 Schottenfeld, D., 441
 Schubert, J., 975
 Schuchter, L. M., 1816
 Schuldes, H., 1723
 Schultz, A., 2446
 Schuurbijs, O., 2229
 Schwaner, I., 161
 Schwartz, A. G., 45
 Schwartz, E. L., 1022, 1574
 Schwarz, R. E., 1635
 Schwella, N., 161
 Scott, G., 2115
 Sears, J. D., 145
 Sebo, T. J., 804

- Seeger, R. C., 2028
 Seemayer, T. A., 1629
 Segalin, A., 425
 Seiki, M., 139
 Seitz, J.-F., 1094
 Sellers, T. A., 494
 Seltzer, M. H., 1822
 Sengupta, A., 2171
 Serova, O., 2219
 Serraino, D., 1004
 Seski, J. C., 1587
 Sesterhenn, I. A., 952, 1641
 Severson, R. K., 441, 2045
 Sham, J. S. T., 869
 Shannon, K. M., 1438
 Shapiro, S., 924
 Shaw, J., 551
 Shay, J. W., 1552
 Sheehan, C. E., 2162
 Shelton, B., 1158
 Shibutani, Y., 169
 Shickell, D., 1629
 Shim, K. S., 1879
 Shimada, H., 892
 Shimizu, A., 688
 Shimomatsuya, T., 220
 Shinozaki, F., 2314
 Shinto, Y., 411
 Shirabe, K., 1487
 Shirai, H., 12
 Shmookler, B. M., 579
 Shoenfeld, Y., 1461
 Shrader-Bogen, C. L., 1977
 Shuper, A., 1241
 Sibug, M.-E., 982
 Siegal, A., 468
 Siegert, W., 161
 Siegfried, S., 1166
 Siena, D. A., 1501
 Silberman, H., 1767
 Silberman, M. A., 772
 Silingardi, V., 1234
 Silva, E. G., 1951
 Silver, B. J., 1362
 Silverstein, M. J., 1862, 1918
 Sim, F. H., 482, 2095
 Simmons, J. F., Jr., 644
 Singer, A. A., 500
 Sinicco, A., 1004
 Skibber, J. M., 1294
 Skjorten, F. J., 1172
 Sleijfer, D. T., 345
 Sloan, J. A., 2193
 Slominski-Caster, S., 2219
 Smart, C. R., 1740
 Smith, M. A., 1903
 Smith, R. B., 648
 Smithson, W. A., 2251
 Sober, A. J., 2361
 Sobin, L. H., 1086, 1656
 Soda, M., 1465
 Soh, S., 90
 Solin, L. J., 1138
 Soong, S.-j., 1122
 Sowa, M., 695
 Spitz, M. R., 1527
 Srivastava, S., 952
 Staal-van den Brekel, A. J., 717
 Stagias, J., 1865
 Stain, S., 1767
 Stajerman, S., 18
 Stapleton, A. M. F., 528
 Steinschifter, W., 1482
 Stephan, C., 104
 Steyerberg, E. W., 345
 Stram, D. O., 2028
 Straus, F. H., II, 1804
 Stroebel, W., 2345
 Sudbø, J., 2200
 Sue-Ling, H., 684
 Sugamura, K., 12
 Sugano, K., 900
 Sukanuma, T., 206
 Sugimasa, Y., 688
 Sugino, T., 362
 Sugiura, H., 255
 Sugiura, M., 269
 Sugiura, Y., 206
 Sugiyama, A., 1069
 Sumi, M., 1516
 Sumida, M., 884
 Sung, M. L., 640
 Surbone, A., 1271
 Surdam, J., 2219
 Sutcliffe, S. B., 1422
 Suzuki, H., 214
 Suzuki, K., 1521
 Suzuki, T., 1647
 Suzuki, Y., 1494, 2237
 Suzuma, T., 1533
 Swanson, G. M., 45
 Swensen, A. R., 2045
 Swenson, K. K., 1923
 Synnestvedt, M., 1816
- T**
 Tagliamonte, M. R., 177
 Tahara, E., 362
 Tahara, H., 362
 Takada, M., 1509
 Takada, N., 1757
 Takahara, O., 1465
 Takahashi, K., 1521
 Takahashi, M., 884
 Takata, A., 2036
 Takemiya, S., 688
 Takenaka, A., 454, 1969
 Takeoka, K., 262
 Takeshima, H., 1014
 Takeshita, M., 1487
 Tamai, S., 688
 Tan, M., 1767
 Tanabe, H., 688
 Tanaka, M., 1890
 Tanaka, R., 1804
 Tanaka, S., 206
 Tanaka, T., 220, 1509
 Tanaka, W., 1509
 Tangoku, A., 1647
 Tanière, P., 1671
 Tanigawa, N., 220
 Tanikawa, K., 1890
 Tanino, H., 1533
 Tara, K., 688
 Tarin, D., 362
 Tartour, E., 1401
 Tatebe, S., 2067
 Tatsuta, M., 454
 Tavassoli, F. A., 1933
 Taylor, S., IV, 588
 Te, V.-C., 906
 Terakawa, N., 521
 Terrier, P., 2371
 Tester, W. J., 724
 Tew, J., Jr., 551
 Thein, T., 2309
 Thiesse, P., 403
 Thomas, R. M., 1086
 Thompson, J. C., 1787
 Thompson, L. D. R., 579
 Thompson, P., 1438
 Tilmann, M. H. M., 1717
 Tinley, S. T., 2066, 2219
 Todd, A. V., 1106
 Todd, K. E., 1780
 Togo, S., 892
 Tokunaga, M., 1465
 Tokuoaka, S., 1465
 Tokuyue, K., 1516
 Tollenaar, R. A. E. M., 1304
 Tom, W. L., 963
 Toner, G. C., 345
 Tonin, P., 2219
 Topham, A., 2409
 Tormey, D. C., 1138
 Tortolero-Luna, G., 505
 Tortoriello, R., 177
 Tournigand, C., 1094, 1100
 Townsend, C. M., Jr., 1787
 Townsend, M. F., 545
 Toyama, K., 1552
 Toyosawa, T., 884
 Traube, M., 1865
 Trendle, M. C., 830
 Tretli, S., 1172

Tsang, R. W., 2414
Tsao, H., 2361
Tsubota, A., 1494
Tsuiji, T., 2314
Tsujitani, S., 2067
Tsukamoto, H., 1287
Tsuneyoshi, M., 3, 1077
Tucker, S. L., 1279
Tyers, G. F. O., 1809

U

Uchida, A., 411
Uchida, T., 90
Ueda, H., 1487
Ueda, T., 411, 1541
Uehara, H., 454
Ufken-Gaul, T., 433
Unni, K. K., 482, 2095
Unterhalt, M., 59
Uozaki, H., 2336
Urist, M. M., 1122

V

Valdés, E., 2178
Validire, P., 1401
Valk, P. E., 115
Vallejo, C., 2320
van Delden, O. M., 1315
van den Berg, H., 2257
VandenBerg, S. R., 989
van den Tweel, J. G., 1548
van der Velden, J., 935
van de Velde, C. J. H., 1304
van Dijk, J. D. P., 935
van Dijkum, E. J. M. N., 1315
van Heerden, J. A., 574
Van Heerden, W. F. P., 2309
van Krieken, J. H., 390
van Lanschot, J. J. B., 1315
van Loosbroek, M., 2229
Varricchio, M., 177
Varvares, M. A., 1623
Vassilakopoulos, G., 2391
Veeder, M., 1138
Veenhof, C. H. N., 935, 2257
Veltri, R. W., 772
Verdonck, L. F., 1548
Verna, A., 1897
Verreet, P., 1871
Vezzoni, G., 2354
Viale, G., 425
Vigani, A., 1897
Villagran-Lillo, R., 2003
Villani, M. R., 1501
Villanueva, A., 1581
Vinciguerra, V., 152
Vlahos, G., 2391
Vogel, C. L., 730

Vogelzang, N. J., 2237
Vokes, E. E., 588
Volk, B., 370
Vollmers, H. P., 433
Volpi, A., 226
von Eschenbach, A. C., 1370
Voulgaris, Z., 2391
Vuitch, F., 1476

W

Wada, S., 780
Wadler, S., 1574
Wallach, R. C., 1574
Walther, M. M., 1964
Wan, J. Y., 1951
Wang, F., 233
Wang, Y., 1022
Wanibuchi, H., 780
Ward, R. L., 1106
Warloe, T., 2282
Warnick, R. E., 551
Warren, R. S., 1664
Watanabe, K., 262
Watson, C. G., 1611
Watson, P., 2066, 2219
Wayne, J., 1804
Webster, A., 730
Weill, S., 18
Weimann, A., 26
Weinstein, J. N., 857
Weitz, I. C., 2024
Wen, B.-C., 612
Wen, S., 2314
Wenger, D. E., 482
Wenig, B. M., 398, 0579
Wennerberg, J. P., 380
Werner, M., 26
Wernert, N., 1646, 1710
West, A. B., 1865
Westerdahl, J., 275
Wheeler, T. M., 528
White, W. L., 1158
Wiernik, P. H., 1022
Wiersma, S. R., 1438
Wilczynski, S. P., 595
Willers, R., 1871
Willett, C. G., 1203
Wilmore, D. W., 1794
Winchester, D. P., 857, 2052
Wingate, P. J., 152
Winick, N. J., 1049
Winski, P. J., 1037
Winstead-Fry, P., 2446
Wolter, J., 730
Wong, W. S., 963
Wong, W. W., 790
Wood, M., 700
Woodman, A., 362

Wörmann, B., 59
Wouters, E. F. M., 717
Wright, T. C., Jr., 505
Wu, X., 1527
Wu, Z.-J., 1944
Wüster, C., 1617

X

Xie, X., 2200
Xie, Y., 595
Xu, H.-J., 1329

Y

Yamaguchi, Y., 474
Yamamoto, K., 1647
Yamamoto, M., 558
Yamamoto, S., 780
Yamamura, S., 255
Yamanaka, J., 1509
Yamanaka, N., 1509
Yamashita, F., 1890
Yao, T., 3, 1077
Yao, Y., 749
Yap, H.-Y., 1150
Yasui, C., 1509
Yates, A. J., 1381
Yellin, A., 468
Yi, S. Y., 1879
Yin, D.-L., 1944
Yokose, T., 1521
Yokozaki, M., 1521
Yoshida, J., 1521
Yoshida, K., 362
Yoshida, M., 688
Yoshida, O., 1180, 1190
Yoshida, S., 900, 1487
Yoshikawa, H., 411
Yoshimasu, T., 1533
Yoshimori, M., 1516
Yoshizaki, T., 139
You, N. C., 462
Younes, N., 1804
Young, W. F., Jr., 804

Z

Zachrau, R. E., 203
Zagars, G. K., 1370
Zaizov, R., 1241
Zakowski, M. F., 356
Zanoni, A., 245
Zarbo, R. J., 2073
Zheng, T., 2209
Ziegler, M. M., 1757
Ziegler, R., 2186
Zimmerman, D., 1044
Zöller, M. E. T., 2125
Zuna, R., 233
Zwiebel, N., 1320